var title_f39_48_40704="Trachyonychia";
var content_f39_48_40704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trachyonychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rough surfaces of nail plates with longitudinal ridging are present in this patient with trachyonychia secondary to alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40704=[""].join("\n");
var outline_f39_48_40704=null;
var title_f39_48_40705="Dobutamine stress CMR predicts viable myocardium";
var content_f39_48_40705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dobutamine stress CMR predicts viable myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dobutamine stress CMR studies in a patient with total occlusion of the left anterior descending artery and a prior anterior wall myocardial infarction.",
"    <br>",
"     (Left upper panel) At rest, the short axis cine CMR at end-diastole shows normal diastolic wall thickness (*).",
"     <br>",
"      (Left lower panel) During systole (left lower panel) there is lack of systolic wall thickening (SWT) of the septum and anteroseptal portion of the anterior wall (arrow).",
"      <br>",
"       (Middle lower panel) During a dobutamine infusion, there was significant induction of SWT (arrow), indicating viable myocardium.",
"       <br>",
"        (Right lower panel) Four months after angioplasty, resting SWT of the anteroseptal region was normal.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reprinted with permission from: the American College of Cardiology (Journal of the American College of Cardiology) 1998; 31:1040.",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.elsevier.com/locate/jacc\">",
"          file://www.elsevier.com/locate/jacc",
"         </a>",
"         <br/>",
"         <a href=\" file://www.sciencedirect.com\">",
"          file://www.sciencedirect.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40705=[""].join("\n");
var outline_f39_48_40705=null;
var title_f39_48_40706="Nail growth";
var content_f39_48_40706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Nail growth: Direction of matrix cell differentiation and movement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40706=[""].join("\n");
var outline_f39_48_40706=null;
var title_f39_48_40707="Streptomycin: Patient drug information";
var content_f39_48_40707=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Streptomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     see \"Streptomycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26917?source=see_link\">",
"     see \"Streptomycin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14595275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Streptomycin for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney function to get worse and hearing loss, and it may change your sense of balance. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702957",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to streptomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hearing loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some side effects may happen up to 2 weeks after the shot. Report them to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11427 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40707=[""].join("\n");
var outline_f39_48_40707=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14595275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015662\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015664\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015663\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015668\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015669\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015671\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015666\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015673\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=related_link\">",
"      Streptomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26917?source=related_link\">",
"      Streptomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_48_40708="Intraabdominal version of transverse lie at cesarean";
var content_f39_48_40708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58320%7EOBGYN%2F76598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58320%7EOBGYN%2F76598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraabdominal version of transverse lie at cesarean",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The assistant performs intra-abdominal version prior to hysterotomy and holds the fetus in its new longitudinal position. The surgeon will then perform the lower-segment uterine incision at the dotted line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breech extractraction of a fetus originally in transverse lie",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After external version from transverse lie to breech, the fetus is extracted in the breech presentation by the operator, while the assistant continuously holds the fetus in longitudinal position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40708=[""].join("\n");
var outline_f39_48_40708=null;
var title_f39_48_40709="Periungual Bowen 2";
var content_f39_48_40709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Periungual Bowen disease (squamous cell carcinoma in situ)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40709=[""].join("\n");
var outline_f39_48_40709=null;
var title_f39_48_40710="Loop diuretics: Maximum effective dose and major side effects";
var content_f39_48_40710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Loop diuretics: Maximum effective dose and major side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     D Craig Brater, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40710/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/48/40710/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics reduce NaCl reabsorption in the thick ascending limb of the loop of Henle. This is achieved by inhibiting the Na-K-2Cl carrier in the luminal membrane in this segment, thereby minimizing the entry of luminal sodium into the cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/1\">",
"     1",
"    </a>",
"    ]. The loop diuretics are highly protein-bound and therefore enter the urine primarily by tubular secretion in the proximal tubule, rather than by glomerular filtration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of the loop diuretics is dose-dependent, being determined largely by the rate at which the diuretic is delivered to its site of action (",
"    <a class=\"graphic graphic_figure graphicRef67654 \" href=\"mobipreview.htm?16/36/16973\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No diuresis is seen with very low doses",
"     </li>",
"     <li>",
"      A progressively increasing diuresis is achieved at higher doses",
"     </li>",
"     <li>",
"      A plateau is reached at which even higher doses produce no further diuresis; this dose is called the maximum effective dose, which increases with worsening renal function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with generalized edema (due for example to heart failure, the nephrotic syndrome, or renal disease) are typically treated with daily therapy. At a given dose, net sodium loss occurs for only one to two weeks before a new steady state is achieved; in this setting, sodium intake and excretion are again equal as the effect of the diuretic is balanced by activation of counterregulatory factors that promote sodium retention, such as the renin-angiotensin system. However, selected patients with mild edema who comply with dietary sodium restriction can be treated with intermittent therapy as needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most commonly used loop diuretics are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , which are sulfonamide derivatives.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"     Ethacrynic acid",
"    </a>",
"    is rarely used because it may be more ototoxic than the sulfonamide diuretics in high doses and its relative insolubility makes it cumbersome to administer intravenously. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Hypersensitivity reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAXIMUM EFFECTIVE DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in subjects with normal renal function indicate that a diuresis begins with as little as 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , with the maximal effect being seen with 40 mg given intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/2\">",
"     2",
"    </a>",
"    ]. If furosemide is given orally, this maximum dose is usually twice the intravenous dose (80 mg) since its bioavailability is only about 50 percent, although there is substantial interpatient and intrapatient variability in the degree of bioavailability of oral furosemide. The equivalent maximal doses are 1 mg for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    and 15 to 20 mg for either oral or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , since these agents are almost completely absorbed. All of the loop diuretics produce the same response if given at equipotent doses. Going above these maximum doses will produce little or no further diuresis but may increase the risk of side effects.",
"   </p>",
"   <p>",
"    The maximum effective diuretic dose differs in patients with heart failure, advanced cirrhosis, or renal failure. In these settings, decreased renal perfusion (and therefore decreased drug delivery to the kidney), diminished proximal secretion (due to the retention of competing anions in renal failure), and enhanced activity of sodium-retaining forces (such as the renin-angiotensin-aldosterone system) singly or in combination can diminish the diuretic effect (",
"    <a class=\"graphic graphic_figure graphicRef67654 \" href=\"mobipreview.htm?16/36/16973\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, the maximal effective intravenous doses in these disorders are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cirrhosis with a relatively normal glomerular filtration rate &ndash; 40 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 1 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 10 to 20 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In heart failure with a relatively normal glomerular filtration rate &ndash; 40 to 80 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 2 to 3 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 20 to 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"       \"Use of diuretics in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In nephrotic syndrome with a relatively normal glomerular filtration rate &ndash; 120 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 3 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"       \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In chronic kidney disease, the upward dose adjustment varies with the severity of the fall in glomerular filtration rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In moderate chronic kidney disease &ndash; 80 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 2 to 3 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 20 to 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In severe chronic kidney disease &ndash; 200 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 8 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 50 to 100 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In oliguric acute kidney injury &ndash; These doses may be adjusted upward to as much as 500 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      (given over 30 to 60 minutes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The extrarenal clearance of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      is increased in renal insufficiency. As a result, the normal ratio of furosemide-to-bumetanide dose falls from 40:1 to about 20:1, or a maximum dose of 8 to 10 mg of bumetanide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe or unstable heart failure may require initial intravenous therapy, since the combination of decreased intestinal perfusion and mucosal edema may markedly slow the rate of drug absorption and therefore the rate of drug delivery to the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/5\">",
"     5",
"    </a>",
"    ]. This defect is generally reversible (thereby allowing the use of oral therapy) with removal of some of the edema fluid and stabilization of cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/5\">",
"     5",
"    </a>",
"    ]. A slower rate of drug absorption also occurs in patients with advanced cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/6\">",
"     6",
"    </a>",
"    ], a setting in which overly rapid diuresis may be a concern. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with marked hypoalbuminemia who do not respond well to intravenous loop diuretics, it has been suggested that the diuresis can be enhanced by infusing a solution in which a loop diuretic has been added to salt-poor albumin, creating loop diuretic-albumin complexes that might increase the rate of loop diuretic secretion into the tubular lumen. However, the efficacy of such an approach has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of refractory edema in adults\", section on 'Infusion with albumin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTRAVENOUS INFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic rationale for a continuous intravenous infusion compared with bolus therapy is related to maintenance of an effective rate of drug excretion and therefore of inhibition of sodium chloride reabsorption in the loop of Henle over time (",
"    <a class=\"graphic graphic_figure graphicRef75714 \" href=\"mobipreview.htm?31/33/32285\">",
"     figure 2",
"    </a>",
"    ). In contrast, bolus therapy is associated with initially higher and then lower rates of diuretic excretion; as a result, sodium excretion may be at near maximal levels for the first two hours but then gradually falls until the next dose is given (",
"    <a class=\"graphic graphic_figure graphicRef75714 \" href=\"mobipreview.htm?31/33/32285\">",
"     figure 2",
"    </a>",
"    ). If a continuous infusion is used, it is important to begin with a bolus to determine that the patient is diuretic-responsive and to quickly achieve therapeutic drug concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/7\">",
"     7",
"    </a>",
"    ]. These issues as well as the data evaluating the efficacy of a continuous infusion versus bolus therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of refractory edema in adults\", section on 'Continuous infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAJOR SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major types of side effects related to loop diuretic use: those related to the diuresis; hypersensitivity reactions, and ototoxicity. A more complete discussion is available on the drug information topic reviews for each loop diuretic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diuresis-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of fluid and electrolyte abnormalities can result from the diuresis or from excessive diuresis. These include hypokalemia, metabolic alkalosis, signs of decreased tissue perfusion such as hypotension and elevations in the blood urea nitrogen and serum creatinine concentration, hyperuricemia, and hyponatremia (primarily due to hypovolemia-induced release of antidiuretic hormone). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/31/502?source=see_link\">",
"     \"Diuretic-induced hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     Furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , which are sulfonamides, can cause hypersensitivity reactions, usually manifested as a rash or rarely acute interstitial nephritis, similar to those produced by other sulfonamide drugs. Patients who develop such reactions can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"     ethacrynic acid",
"    </a>",
"    , which is not a sulfonamide. Ethacrynic acid is rarely used in the absence of this indication because it may be more ototoxic than the sulfonamide diuretics in high doses and its relative insolubility makes it cumbersome to administer intravenously.",
"   </p>",
"   <p>",
"    A separate issue is the risk of an allergic reaction to the sulfonamide-based loop diuretics in patients with known sulfonamide antibiotic allergy. There is minimal evidence of allergic cross-reactivity between sulfonamide antimicrobials and non-antimicrobials. Thus, patients with a history of allergy to sulfonamide antimicrobial drugs would be expected to tolerate non-antimicrobial sulfonamides such as loop diuretics. Allergic reactions that do occur appear to be related to a predisposition to allergic reactions rather than sulfonamide cross-reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40710/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=see_link&amp;anchor=H22#H22\">",
"     \"Sulfonamide allergy in non HIV-infected patients\", section on 'Between sulfonamide antimicrobials and non-antimicrobials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ototoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretic-induced ototoxicity, which can lead to deafness that may be permanent, primarily occurs with high-dose intravenous therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    doses above 240",
"    <span class=\"nowrap\">",
"     mg/h)",
"    </span>",
"    or at lower doses in patients with renal failure or concurrent aminoglycoside therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"     Ethacrynic acid",
"    </a>",
"    , which is now rarely used, may be more ototoxic in high doses than furosemide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    . These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of refractory edema in adults\", section on 'Risk of ototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       \"Patient information: Dealing with side effects from medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11153326\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effects of loop diuretics are dose-dependent. Sodium excretion is determined largely by the rate at which the diuretic is delivered to its site of action in the tubular lumen: no diuresis is seen with very low doses, whereas an increasing effect is achieved at higher doses. A plateau is eventually reached in which even higher doses produce no further diuresis; this dose is called the maximum effective dose (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with normal renal function may respond to as little of 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , with the maximal effect observed with 40 mg given intravenously. Higher doses produce little or no further diuresis but increase the risk of side effects. The equivalent dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      is 1 mg and of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      is 15 to 20 mg either oral or intravenous. All of the loop diuretics produce the same response if given at equipotent doses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maximum effective dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effective diuretic dose that is achieved with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      should be doubled for oral furosemide, since its bioavailability is only about 50 percent. There is, however, substantial interpatient and intrapatient variability in the degree of bioavailability of oral furosemide. Thus, the dose should be governed by the diuretic response; estimates of bioavailability are used only as a guide to initial therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maximum effective dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The maximum effective diuretic dose differs in edematous patients with cirrhosis, heart failure, nephrotic syndrome, or renal failure. The maximal effective",
"      <strong>",
"       intravenous",
"      </strong>",
"      doses in these disorders are: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maximum effective dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In cirrhosis with a relatively normal glomerular filtration rate &ndash; 40 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 1 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 10 to 20 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"       \"Initial therapy of ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In heart failure with a relatively normal glomerular filtration rate &ndash; 40 to 80 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 2 to 3 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 20 to 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"       \"Use of diuretics in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In nephrotic syndrome with a relatively normal glomerular filtration rate &ndash; 120 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 3 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"       \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with renal insufficiency, upward dose adjustment varies with the severity of the fall in glomerular filtration rate: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maximum effective dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In moderate renal insufficiency &ndash; 80 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 2 to 3 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 20 to 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In severe renal insufficiency &ndash; 200 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 8 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , or 50 to 100 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe or unstable heart failure may require initial intravenous therapy because drug absorption may be slowed by decreased intestinal perfusion and mucosal edema. This defect is generally reversible (thereby allowing the use of oral therapy) with removal of some of the edema fluid and stabilization of cardiac function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maximum effective dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loop diuretics administered as a continuous intravenous infusion may be safer and more effective than bolus injections in patients with refractory edema. It is important to begin with a bolus to determine that the patient is diuretic-responsive and to quickly achieve therapeutic drug concentrations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intravenous infusion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of refractory edema in adults\", section on 'Continuous infusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Loop diuretics can lead to a variety of adverse effects:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loop diuretics can induce a variety of fluid and electrolyte abnormalities that can result from the diuresis or from excessive diuresis. These include hypokalemia, metabolic alkalosis, signs of decreased tissue perfusion such as hypotension and elevations in the blood urea nitrogen and serum creatinine concentration, hyperuricemia, and hyponatremia (primarily due to water ingestion combined with hypovolemia-induced release of antidiuretic hormone). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diuresis-related'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       Furosemide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      , which are sulfonamides, can cause hypersensitivity reactions, usually manifested as a rash or rarely acute interstitial nephritis, similar to those produced by other sulfonamide drugs. Patients who develop such reactions can be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"       ethacrynic acid",
"      </a>",
"      , which is not a sulfonamide.",
"      <br/>",
"      <br/>",
"      There is minimal evidence of allergic cross-reactivity between sulfonamide antimicrobials and non-antimicrobials. Thus, patients with a history of allergy to sulfonamide antimicrobial drugs would be expected to tolerate non-antimicrobial sulfonamides such as loop diuretics. Allergic reactions that do occur appear to be related to a predisposition to allergic reactions rather than sulfonamide cross-reactivity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loop diuretic-induced ototoxicity, which can lead to deafness that may be permanent, primarily occurs with high-dose intravenous therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      doses above 240",
"      <span class=\"nowrap\">",
"       mg/h)",
"      </span>",
"      or at lower doses in patients with renal failure or concurrent aminoglycoside therapy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"       Ethacrynic acid",
"      </a>",
"      , which is now rarely used, may be more ototoxic in high doses than furosemide,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      . These issues are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of refractory edema in adults\", section on 'Risk of ototoxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/1\">",
"      Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994; 23:623.",
"     </a>",
"    </li>",
"    <li>",
"     Brater, DC, Voelker, JR. Use of diuretics in patients with renal disease. In: Contemporary Issues in Nephrology. Pharmacotherapy of Renal Disease and Hypertension, vol 17, Bennett, WM, McCarron, DA (Eds), Churchill Livingstone, New York, 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/3\">",
"      Brater DC, Anderson SA, Brown-Cartwright D. Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther 1986; 40:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/4\">",
"      Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/5\">",
"      Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/6\">",
"      Fredrick MJ, Pound DC, Hall SD, Brater DC. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther 1991; 49:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/7\">",
"      Brater DC. Diuretic therapy. N Engl J Med 1998; 339:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40710/abstract/8\">",
"      Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2310 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40710=[""].join("\n");
var outline_f39_48_40710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11153326\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAXIMUM EFFECTIVE DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTRAVENOUS INFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAJOR SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diuresis-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11153326\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2310|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/36/16973\" title=\"figure 1\">",
"      Loop diuretic dose response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/33/32285\" title=\"figure 2\">",
"      First dose diuretic response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/31/502?source=related_link\">",
"      Diuretic-induced hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_48_40711="Paraneoplastic brainstem encephalitis";
var content_f39_48_40711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic brainstem encephalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph from a section of brainstem from a patient with colon cancer and paraneoplastic brainstem encephalitis associated with anti-Ma2 antibodies. There is a perivascular lymphocytic infiltrate on the right side (large arrow), while the middle shows several reactive astrocytes (gliosis) and a neuron undergoing degeneration (small arrow). Parenchymal infiltrates of mononuclears cells are more apparent on the left side of the picture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josep Dalmau, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40711=[""].join("\n");
var outline_f39_48_40711=null;
var title_f39_48_40712="Placental vasculature";
var content_f39_48_40712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Placental vasculature",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 571px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vander AJ, Sherman JH, Luciano DS. Human Physiology, 6th ed, McGraw-Hill, Inc 2001. p.679. Original Figure 19-24. Copyright &copy; 2001 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40712=[""].join("\n");
var outline_f39_48_40712=null;
var title_f39_48_40713="Neonatal herpes simplex virus infection: Management and prevention";
var content_f39_48_40713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal herpes simplex virus infection: Management and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Gail J Demmler-Harrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40713/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/48/40713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal infection with herpes simplex virus (HSV) occurs in 1 out of every 3200 live births, causes serious morbidity and mortality, and leaves many survivors with permanent sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite this seemingly low prevalence, neonatal HSV accounts for 0.2 percent of neonatal hospitalizations and 0.6 percent of in-hospital neonatal deaths in the United States, and is associated with substantial healthcare resource utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the discovery of neonatal HSV disease in the 1930s, important breakthroughs in understanding how HSV is transmitted to the fetus and neonate, molecular methods to diagnose HSV, and antiviral treatment strategies have improved diagnosis and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2\">",
"     2",
"    </a>",
"    ]. However, despite these advances, neonatal HSV remains a clinical challenge.",
"   </p>",
"   <p>",
"    The management and prevention of neonatal HSV infection will be reviewed here. The clinical features and diagnosis of neonatal HSV infection and nonneonatal herpes simplex virus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=see_link\">",
"     \"Herpetic gingivostomatitis in young children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of neonatal herpes simplex virus (HSV) infection involves supportive measures and antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive measures and special or intensive measures for the critically ill neonate with disseminated or central nervous system (CNS) disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid maintenance (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27591?source=see_link\">",
"       \"Fluid and electrolyte therapy in newborns\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link\">",
"       \"Maintenance fluid therapy in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Correction of hypoglycemia and electrolyte imbalances (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link\">",
"       \"Approach to hypoglycemia in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Management of disseminated intravascular coagulation, systemic inflammatory response, and shock, including fresh frozen plasma and platelet transfusions (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link&amp;anchor=H29#H29\">",
"       \"Disseminated intravascular coagulation in infants and children\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Control of seizures (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"       \"Treatment of neonatal seizures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Provision of oxygen and mechanical ventilator support",
"     </li>",
"     <li>",
"      Nutritional support",
"     </li>",
"     <li>",
"      Antimicrobial treatment for secondary bacterial infections, especially for gram negative organisms in neonates with ascites and liver necrosis",
"     </li>",
"     <li>",
"      Intravenous immune globulin, especially if myocardial",
"      <span class=\"nowrap\">",
"       dysfunction/myocarditis",
"      </span>",
"      or systemic inflammatory response is present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Other interventions, such as glucocorticoids or exchange transfusion; liver transplantation is reported in single case reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACYCLOVIR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    as the antiviral agent of choice for the treatment of neonatal herpes simplex virus (HSV) infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In a randomized controlled trial, the morbidity and mortality were similar among infants treated with acyclovir and vidarabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/9\">",
"     9",
"    </a>",
"    ]. However, vidarabine has systemic toxicity and a dosing schedule that requires 12-hour infusions.",
"   </p>",
"   <p>",
"    The mechanism of action, pharmacokinetics, and toxicity of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    should be administered at the time the diagnosis of neonatal HSV is",
"    <strong>",
"     suspected",
"    </strong>",
"    . Prompt administration improves outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,8,9,11,12\">",
"     2,8,9,11,12",
"    </a>",
"    ]. Acyclovir therapy should be continued while clinical observation and results of laboratory and imaging evaluations are completed.",
"   </p>",
"   <p>",
"    The indications for initiation of empiric",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    are not standardized. Most experts agree that empiric acyclovir is indicated for neonates with clinical features suggestive of HSV infection, which include mucocutaneous vesicles (",
"    <a class=\"graphic graphic_picture graphicRef75059 graphicRef56041 graphicRef78598 \" href=\"mobipreview.htm?26/55/27513\">",
"     picture 1A-C",
"    </a>",
"    ), seizures, lethargy, respiratory distress, thrombocytopenia, coagulopathy, blood oozing from intravascular catheter sites, hypothermia, sepsis-like illness, hepatomegaly, ascites, or markedly elevated transaminases (",
"    <a class=\"graphic graphic_figure graphicRef67814 \" href=\"mobipreview.htm?3/42/3758\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7,13-15\">",
"     7,13-15",
"    </a>",
"    ]. However, expert opinions differ regarding the relative benefits, risks, and cost-effectiveness of empiric acyclovir before virologic confirmation in other clinical situations (eg, cerebrospinal fluid (CSF) pleocytosis with a predominance of mononuclear cells in an otherwise well-appearing infant, persistent or recurrent erythema or",
"    <span class=\"nowrap\">",
"     purulence/crusting",
"    </span>",
"    at the site of a scalp electrode, fever without localizing signs in an infant &le;21 days of age, etc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The full course of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy should be administered for infants with positive HSV cultures or DNA polymerase chain reaction (PCR), and infants with negative virologic studies in whom neonatal HSV is strongly suspected. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive laboratory evaluation for HSV should be performed before initiation of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy. The evaluation should include (if the infant is clinically stable enough to undergo it) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7,17\">",
"     7,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count, including differential and platelet count",
"     </li>",
"     <li>",
"      Liver transaminases, total and direct bilirubin, ammonia (ammonia should be performed to exclude liver failure and metabolic disease in neonates with elevated liver enzymes and fulminant sepsis, but is not necessary for all neonates with suspected HSV)",
"     </li>",
"     <li>",
"      Blood urea nitrogen (BUN), creatinine, and urinalysis (to assess renal function and hydration status)",
"     </li>",
"     <li>",
"      Blood HSV DNA PCR",
"     </li>",
"     <li>",
"      CSF cell count and differential, glucose, protein, HSV DNA PCR",
"     </li>",
"     <li>",
"      Viral culture of tracheal aspirate, if intubated",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Swabs/scrapings",
"      </span>",
"      of skin or mucous membrane lesions for viral culture HSV and for direct immunofluorescence assay (DFA) in selected cases where skin lesions are present",
"     </li>",
"     <li>",
"      Surface cultures from the conjunctivae, mouth, nasopharynx, and rectum (some experts suggest swab specimens from the conjunctivae, mouth, nasopharynx, and rectum can be obtained with a single swab&mdash;starting with eyes and ending with the rectum&mdash;and placed in one viral transport media tube, or collected with multiple swabs, which are then placed in a single viral transport media tube)",
"     </li>",
"     <li>",
"      Chest radiograph, for neonates with respiratory distress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link&amp;anchor=H14#H14\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    for all forms of neonatal HSV is 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously divided every eight hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8\">",
"     8",
"    </a>",
"    ]. The dose of acyclovir must be adjusted for neonates with renal failure.",
"   </p>",
"   <p>",
"    The benefits of this dose compared to standard-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day were established in an open-label study in which 72 neonates with CNS or disseminated HSV were treated with acyclovir 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8\">",
"     8",
"    </a>",
"    ]. Their outcomes were compared with those of infants in an earlier trial who were treated with acyclovir 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/9\">",
"     9",
"    </a>",
"    ]. The higher dose was associated with increased survival at 24 months (odds ratio [OR] 3.3, 95% CI 1.5-7.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy for neonatal HSV infection depends upon the pattern of illness and response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,7,8,10\">",
"     2,7,8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Localized skin, eye, and mouth disease should be treated for a minimum of 14 days if disseminated and CNS disease have been excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link&amp;anchor=H14#H14\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disseminated and central nervous system (CNS) disease should be treated for a",
"    <strong>",
"     minimum",
"    </strong>",
"    of 21 days. Because the persistence of HSV DNA in the CSF is associated with poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/18\">",
"     18",
"    </a>",
"    ], repeat lumbar puncture to obtain CSF HSV DNA PCR near the end of therapy is recommended to make sure that HSV DNA PCR is negative and that CSF parameters have returned to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,17,19-21\">",
"     2,17,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To assure adequate therapy, many experts recommend continuing antiviral therapy and repeat CSF HSV DNA PCR testing weekly until HSV DNA PCR is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17\">",
"     17",
"    </a>",
"    ]. Some experts also recommend serial monitoring of blood HSV DNA PCR on a weekly basis; HSV DNA PCR should be negative before",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/21\">",
"     21",
"    </a>",
"    ]. Other experts do not recommend serial testing of blood PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. The clinical significance of persistently positive blood PCR is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even after successful parenteral treatment, recurrence of HSV can occur and may be a lifelong problem for the patient and family. Fortunately, recurrence of CNS disease is rare. However, recurrent vesicles at sites in the skin, eyes, and mouth are common and occur in 60 to 80 percent of neonates, with 1 to 12 episodes in the first year of life. Therefore, some experts recommend long-term suppressive therapy with oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    to reduce skin or eye recurrences during infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2\">",
"     2",
"    </a>",
"    ]. Recurrence of CNS disease, as well as emergence of acyclovir-resistant HSV mutants, has occurred in neonates who were receiving oral acyclovir suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Suppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of neonatal HSV disease with antiviral therapy improves survival and outcome, especially if treatment is begun early in the course of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before antiviral therapy was available, the one-year mortality rates for neonates with disseminated and central nervous system HSV disease were 85 and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/26\">",
"     26",
"    </a>",
"    ]. With the advent of antiviral therapy, mortality rates declined to 29 and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,9,17\">",
"     8,9,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiviral therapy also has increased the proportion of survivors of disseminated disease who have normal neurologic development (from 50 to approximately 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,17,26\">",
"     8,17,26",
"    </a>",
"    ]. Antiviral therapy does not appear to have affected the proportion of survivors of CNS disease with normal neurologic development (approximately 30 percent both before and after antiviral therapy became available) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,17,26\">",
"     8,17,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early antiviral treatment of infants with skin, eye, and mouth (SEM) disease prevents progression to CNS or disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/21\">",
"     21",
"    </a>",
"    ]. Between 50 and 60 percent of infants with SEM who do not receive antiviral therapy progress to CNS or disseminated disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy is well tolerated by most neonates. Side effects are unusual. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcers at the site of peripheral extravasation.",
"     </li>",
"     <li>",
"      Renal failure caused by crystallization in the renal tubules, which is more likely to occur if the neonate is dehydrated; maintain urine-specific gravity &lt;1.010 to reduce the risk of this adverse effect.",
"     </li>",
"     <li>",
"      Seizures, especially if the dose is not adjusted in patients with impaired renal function or renal failure.",
"     </li>",
"     <li>",
"      Dose-dependent reversible neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,8,17\">",
"       2,8,17",
"      </a>",
"      ]; absolute neutrophil counts should be followed approximately twice per week during the course of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,17\">",
"       8,17",
"      </a>",
"      ]. The",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      dosage should be reduced or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/27/44470?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      should be administered if the absolute neutrophil count remains below",
"      <span class=\"nowrap\">",
"       500/microL",
"      </span>",
"      for an extended period of time and there is not an alternative explanation for the neutropenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest suppressive therapy with oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose three times per day for six months immediately following parenteral treatment for all forms of neonatal HSV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]. This recommendation is based on evidence that suppression may influence favorable outcome in CNS disease and reduce cutaneous recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral suppression with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose three times per day or 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose three times per day or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/35/3638?source=see_link\">",
"     valacyclovir",
"    </a>",
"    for at least six months is also used to reduce cutaneous or ophthalmologic recurrences during infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Cutaneous recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is preferred to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/35/3638?source=see_link\">",
"     valacyclovir",
"    </a>",
"    because the safety and efficacy of valacyclovir have not been established in infants younger than two years of age. Furthermore, since only tablet form is available, an extemporaneously compounded valacyclovir oral suspension (25 to 50",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    must be specially prepared for infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/28\">",
"     28",
"    </a>",
"    ]. Based on limited data on the pharmacokinetics and safety of valacyclovir in pediatric patients, doses of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of extemporaneously compounded valacyclovir oral suspension, administered twice daily, produce favorable acyclovir blood concentrations and appear well tolerated in most children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of long-term suppression with oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    in reducing the risk of CNS recurrence after neonatal HSV disease is unknown. CNS recurrence in neonates receiving long-term oral suppression has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/24\">",
"     24",
"    </a>",
"    ]. Nonetheless, oral acyclovir suppression appears to be associated with improved neurodevelopmental outcome. In a multicenter trial, 74 infants (45 with CNS HSV disease, 29 with SEM HSV disease) were randomly assigned to oral acyclovir 300",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per dose three times per day or placebo immediately following parenteral acyclovir treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/27\">",
"     27",
"    </a>",
"    ]. In children with CNS involvement, acyclovir suppression was associated with higher mean infant development scores at 12 months of age (88 versus 68 on the Bayley Scales of Infant Development, 2",
"    <sup>",
"     nd",
"    </sup>",
"    edition in which scores range from 50 to 150). The incidence and degree of neutropenia were similar in the treatment and placebo groups.",
"   </p>",
"   <p>",
"    Adverse effects of oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    suppression may include dose-dependent reversible neutropenia (in one-half to two-thirds of infants in previous studies) and emergence of HSV mutants that are acyclovir resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,17,24,25\">",
"     2,17,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    suppressive therapy for six months immediately following parenteral acyclovir for neonatal HSV disease, including SEM, CNS, and disseminated HSV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/21,27\">",
"     21,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239728820\">",
"    <span class=\"h1\">",
"     2012 IV ACYCLOVIR SHORTAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of November 2012, there is a shortage of intravenous (IV)",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States related to a manufacturing delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/31\">",
"     31",
"    </a>",
"    ]. Neonates with proven herpes simplex virus (HSV) disease are a priority group for existing supplies of IV acyclovir. However, if IV acyclovir is not available, in agreement with the American Academy of Pediatrics Committee on Infectious Diseases, we suggest IV",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    as a first-line alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]; the dose is 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours IV for infants &le;90 days of age and 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours IV for infants &gt;90 days. We suggest IV",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/4/24646?source=see_link\">",
"     foscarnet",
"    </a>",
"    as a second-line alternative; the dose is 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours IV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF HSV EYE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with ocular herpes simplex virus (HSV) involvement, such as keratitis, should receive a topical ophthalmic solution (eg, 1 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/47/43762?source=see_link\">",
"     trifluridine",
"    </a>",
"    , 0.1 percent iododeoxyuridine, or 3 percent vidarabine) in addition to systemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. They should also be referred to an ophthalmologist for consultation.",
"   </p>",
"   <p>",
"    Suppressive therapy with oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    may be warranted for patients with HSV involvement of the eye if there is a risk of impaired vision with reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Suppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of neonatal herpes simplex virus (HSV) disease depends upon the clinical pattern. HSV infection is lifelong, even with appropriate therapy. Recurrence of mucocutaneous lesions, eye disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system disease may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The one-year mortality rate for disseminated disease is 29 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk of mortality is increased in infants with lethargy, severe hepatitis, acute liver failure, coma or near-coma at the time of presentation, disseminated intravascular coagulopathy, prematurity, and pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17,34,35\">",
"     17,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 80 percent of survivors of disseminated neonatal HSV disease may have normal neurologic development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,17,26\">",
"     8,17,26",
"    </a>",
"    ]. The risk of neurodevelopmental abnormalities (eg, developmental delay, hemiparesis, persistent seizures, microcephaly, blindness) is increased among infants with seizures at or before the initiation of antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe hepatitis, caused by either HSV-1 or -2, may cause potentially fatal, acute liver failure in neonates with disseminated disease. Liver transplantation has been carried out successfully in a few reported neonates with fulminant hepatic failure associated with disseminated neonatal HSV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     CNS disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The one-year mortality rate for central nervous system (CNS) disease is 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8\">",
"     8",
"    </a>",
"    ]. Prematurity, seizures, and coma or near-coma at the time of presentation are associated with increased risk of mortality in CNS disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17,34,35\">",
"     17,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 30 percent of survivors of neonatal CNS HSV have normal neurologic development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,17,26\">",
"     8,17,26",
"    </a>",
"    ]. The risk of neurodevelopmental abnormalities is increased among infants with seizures at or before the initiation of antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Skin, eye, and mouth disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality is rare in neonatal HSV disease that is localized to the skin, eye, and mouth (in whom disseminated and CNS disease have been appropriately excluded). Less than 2 percent of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    recipients have developmental delay after recovery from neonatal SEM HSV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8,9,17\">",
"     8,9,17",
"    </a>",
"    ]. The risk of neurodevelopmental abnormalities is increased in infants with &ge;3 recurrences of skin lesions before six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cutaneous recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of infants who survive neonatal HSV disease have cutaneous recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. Cutaneous recurrence of HSV may occur throughout life. Infants with &ge;3 cutaneous recurrences during the first six months of life are at increased risk of neurodevelopmental abnormalities at follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/35\">",
"     35",
"    </a>",
"    ]. Recurrence of skin lesions may affect child care arrangements and is disruptive to the lives of patients and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of cutaneous recurrence is not established. However, treatment doses of oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose three times per day for young infants, or 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose four to five times per day for older infants and children) may be administered early at the time of each cutaneous recurrence to reduce the discomfort and shedding associated with the lesions, or preemptively, for a brief period of one to two weeks, when a cutaneous recurrence is anticipated, such as times of high stress or exposure to sunlight, to try and prevent a recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with frequent cutaneous recurrences that are painful or disruptive to daily life, long-term oral suppression may be of benefit. There is a broad range of acceptable doses. The author of this topic review generally prefers",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose twice per day, but in some patients, 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose twice per day is effective. Suppression may be discontinued, and the patient observed, if no cutaneous recurrences are documented after a 12-month period.",
"   </p>",
"   <p>",
"    An increase of the frequency to three or four times daily for a brief period of time may be of benefit if a recurrence \"breaks through\" twice-daily oral suppression. HSV lesions that occur while the patient is receiving",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    three to four times per day should be cultured and the HSV isolate tested for acyclovir resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LONG-TERM FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of neonatal herpes simplex virus (HSV) infection, especially infants with involvement of the central nervous system, should be followed closely for achievement of developmental milestones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17\">",
"     17",
"    </a>",
"    ]. They should undergo formal neurodevelopmental assessments as indicated. Referral to early intervention programs (eg, physical therapy, occupational therapy, speech therapy) should be made at the earliest sign of potential impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Audiologic assessments are usually recommended, as well. However, evidence suggests that the incidence of hearing loss after neonatal HSV disease is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If eye disease was present, careful follow-up with an ophthalmologist may be indicated. The family should be counseled to seek medical care promptly if symptoms of eye disease recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies for prevention of intrauterine and perinatally acquired herpes simplex virus (HSV) infection, including identification of high-risk pregnant women, cesarean delivery, maternal antiviral therapy, and anticipatory guidance for pregnant women and partners, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link&amp;anchor=H35#H35\">",
"     \"Genital herpes simplex virus infection and pregnancy\", section on 'Screening pregnant women with no HSV history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postnatal transmission of HSV can be prevented by counseling family members with HSV lesions (cold sores, herpetic whitlow, herpetic gingivostomatitis) to avoid close contact with and kissing the newborn infant. Women with herpetic breast lesions should not breastfeed from the affected breast until the lesions have resolved because direct contact with the lesions may transmit the herpes simplex virus to the infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/40\">",
"     40",
"    </a>",
"    ]. Mothers should use careful hand hygiene and cover any lesions with which the infant might come into contact.",
"   </p>",
"   <p>",
"    Infants born to women with",
"    <strong>",
"     active HSV lesions",
"    </strong>",
"    should be managed with contact precautions during hospitalization, with a private room, or while rooming with the mother [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. Some experts suggest that contact precautions are not necessary for such infants who are born by cesarean delivery &lt;4 hours after rupture of membranes. Contact precautions are not necessary for infants born to women with a history of",
"    <strong>",
"     recurrent",
"    </strong>",
"    genital HSV who have no genital lesions at the time of delivery.",
"   </p>",
"   <p>",
"    Contact precautions also should be used for infants who are hospitalized with HSV infection if they have mucocutaneous lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. The median duration of viral shedding from skin vesicles and mucosal lesions in infants receiving",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy is five to eight days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8\">",
"     8",
"    </a>",
"    ]. However, contact precautions may be continued for a longer period of time if the patient is hospitalized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"     \"General principles of infection control\", section on 'Contact precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and children with cutaneous recurrence of neonatal HSV should be counseled to cover the lesions to prevent potential transmission through direct contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no licensed, effective vaccine against HSV-1 or HSV-2 infection. However, a candidate HSV-2 gD subunit vaccine is in phase III clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,42\">",
"     2,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE ASYMPTOMATIC EXPOSED INFANT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421546997\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of asymptomatic infants who are exposed to maternal herpes simplex virus (HSV) at delivery (as documented by maternal virologic testing or active genital lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/10\">",
"     10",
"    </a>",
"    ]) has not been evaluated in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/21\">",
"     21",
"    </a>",
"    ]. However, experts and expert groups provide some guidelines regarding the need for cultures and prophylactic or anticipatory antiviral therapy based upon the risk of transmission under various circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7,10,43-47\">",
"     7,10,43-47",
"    </a>",
"    ]. Consultation with a specialist in pediatric infectious diseases is suggested for guidance in difficult clinical situations.",
"   </p>",
"   <p>",
"    The risk of transmission to the infant depends upon a number of factors, including (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link&amp;anchor=H21#H21\">",
"     \"Genital herpes simplex virus infection and pregnancy\", section on 'Predictors of neonatal infection'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whether the maternal infection is primary or recurrent",
"     </li>",
"     <li>",
"      Maternal HSV antibody status",
"     </li>",
"     <li>",
"      Duration of rupture of membranes",
"     </li>",
"     <li>",
"      The integrity of mucocutaneous barriers (eg, the use of fetal scalp electrodes)",
"     </li>",
"     <li>",
"      Cesarean versus vaginal delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of transmission is greatest (25 to 60 percent) for infants delivered vaginally or &ge;4 hours after rupture of membranes to mothers with active genital lesions and no history of HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/1,7,21,47\">",
"     1,7,21,47",
"    </a>",
"    ]. The risk of transmission is lower (&lt;2 percent) for infants delivered vaginally or &ge;4 hours after rupture of membranes to mothers with recurrent HSV infection and active genital lesions. The risk of transmission is lowest among infants born by cesarean delivery within four hours of rupture of membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7,21\">",
"     7,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Availability of type-specific polymerase chain reaction (PCR) or culture testing of maternal genital lesions and type-specific maternal HSV serology permits more accurate characterization of the type of maternal infection (",
"    <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"     table 1",
"    </a>",
"    ) and, therefore, estimation of the risk of transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/1,47\">",
"     1,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2013 American Academy of Pediatrics (AAP) clinical report on the management of asymptomatic infants born to women with active genital herpes lesions provides guidance on the evaluation and management of asymptomatic neonates in settings were type-specific HSV testing with rapid turn-around time is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ]. The approach that is described in the sections that follow is consistent with the 2013 AAP guidelines, but also provides recommendations for settings where type-specific HSV serologic testing with rapid turn-around time is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421547421\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All neonates who are born to women with active genital HSV lesions or a history of genital HSV but no active lesions at the time of delivery should be monitored for clinical evidence of HSV infection (eg, skin or scalp rashes, conjunctival lesions, irritability, sepsis, etc) (",
"    <a class=\"graphic graphic_figure graphicRef67814 \" href=\"mobipreview.htm?3/42/3758\">",
"     figure 1",
"    </a>",
"    ) during the first six weeks of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. The infant's parents and caregivers should be educated about the signs of neonatal HSV infection.",
"   </p>",
"   <p>",
"    Infants who develop clinical evidence of HSV infection should undergo full clinical and virologic evaluation (including HSV blood PCR; surface cultures; CSF HSV PCR, cell count, and chemistries; and serum alanine aminotransferase [ALT] and aspartate aminotransferase [AST]; complete blood count [CBC] with differential and platelet count) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously (IV) divided every eight hours should be administered while results of virologic evaluation are pending. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link&amp;anchor=H14#H14\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Laboratory evaluation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Acyclovir therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H570590993\">",
"    <span class=\"h2\">",
"     Maternal history of HSV, no active lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transmission of HSV to infants born to women with a history of genital HSV but no active genital lesions at the time of delivery is low. Such infants who are asymptomatic should be monitored for neonatal HSV infection. However, we do not suggest that they be evaluated for neonatal HSV or receive prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H421547421\">",
"     'Monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510233438\">",
"    <span class=\"h2\">",
"     Maternal history of HSV, active lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transmission of HSV to infants born to women with a history of genital HSV and active genital lesions at the time of delivery HSV is relatively low (&lt;2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/1,7,21,47\">",
"     1,7,21,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that the evaluation of asymptomatic infants born to women with a history of genital HSV and active genital lesions at the time of delivery include the following studies obtained at 12 to 24 hours of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7,21,47\">",
"     7,21,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surface cultures (ie, swabs of the mouth, nasopharynx, conjunctivae, rectum, scalp electrode site [if present] and possibly urine for viral culture)",
"     </li>",
"     <li>",
"      HSV blood PCR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surface cultures obtained before 12 to 24 hours may reflect contamination during delivery, rather than infection. The sensitivity of viral cultures for detecting neonatal HSV infection in infants whose mothers were treated with antiviral medication during pregnancy is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the surface cultures or blood HSV PCR are positive, the asymptomatic neonate should undergo full virologic evaluation (CSF for HSV PCR, cell count, chemistries; serum ALT and AST; CBC with differential and platelet count) and be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV divided every eight hours. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Acyclovir therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We do not routinely suggest prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    for asymptomatic neonates who are born to women with a history of genital HSV and active genital lesions at the time of delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV divided every eight hours may be warranted (after full HSV evaluation, including HSV blood PCR; surface cultures; CSF HSV PCR, cell count, and chemistries; serum ALT and AST; CBC with differential and platelet count) for asymptomatic neonates born to women with recurrent HSV infection and additional risk factors for transmission (eg, rupture of membranes &gt;4 to 6 hours, gestation &lt;37 weeks, scalp electrode, skin lacerations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/1,47\">",
"     1,47",
"    </a>",
"    ]. If acyclovir is initiated for such patients, it may be discontinued after three to five days if the infant remains asymptomatic and HSV PCR and viral cultures are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510233446\">",
"    <span class=\"h2\">",
"     No maternal history of HSV, active lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transmission of HSV to infants born to women with no history of genital HSV and active genital lesions at the time of delivery is between 25 and 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2,7,21\">",
"     2,7,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that the evaluation of asymptomatic infants born to women with no history of genital HSV and active genital lesions include the following studies obtained at approximately 24 hours of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surface cultures (ie, swabs of the mouth, nasopharynx, conjunctivae, rectum, scalp electrode site [if present] and possibly urine for viral culture)",
"     </li>",
"     <li>",
"      HSV blood PCR",
"     </li>",
"     <li>",
"      CSF HSV PCR, cell count, chemistries",
"     </li>",
"     <li>",
"      Serum ALT and AST",
"     </li>",
"     <li>",
"      Complete blood count with differential and platelet count",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also suggest sending maternal blood for type-specific HSV serology as soon as possible after delivery (if available) to more accurately characterize maternal infection (",
"    <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surface cultures obtained before 12 to 24 hours may reflect contamination during delivery, rather than infection. The sensitivity of viral cultures for detecting neonatal HSV infection in infants whose mothers were treated with antiviral medication during pregnancy is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that asymptomatic neonates born to women with no history of genital HSV and active genital lesions at the time of delivery be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV divided every eight hours after evaluation for HSV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    is determined by the neonate&rsquo;s clinical status, results of the neonate&rsquo;s evaluation for HSV disease, and maternal HSV infection classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For neonates born to women with active genital HSV lesions and no history of genital HSV infection in whom",
"      <strong>",
"       type-specific HSV serologic testing is not available",
"      </strong>",
"      who remain asymptomatic and whose HSV evaluation is negative, we suggest that prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      be continued for 10 days.",
"     </li>",
"     <li>",
"      For neonates born to women with active genital HSV lesions and no history of genital HSV infection but",
"      <strong>",
"       recurrent HSV infection (by serologic testing",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"       table 1",
"      </a>",
"      )) who remain asymptomatic, we suggest that",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      be discontinued at 48 to 72 hours if HSV PCR and viral studies are negative.",
"     </li>",
"     <li>",
"      For neonates born to women with",
"      <strong>",
"       primary genital HSV",
"      </strong>",
"      infection or nonprimary",
"      <strong>",
"       first episode genital HSV",
"      </strong>",
"      infection (based on serologic testing (",
"      <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"       table 1",
"      </a>",
"      )) or assumed primary or nonprimary first episode infection (based on strong clinical suspicion and discordant or unavailable genital and serologic test results) who remain asymptomatic and whose HSV evaluation is negative, we suggest that",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      be continued for 10 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all cases, if the infant becomes symptomatic or the HSV evaluation is abnormal (including positive PCR, culture, abnormal CSF, or serum ALT or AST more than two times the upper limit of normal), we recommend that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    be continued for at least 14 days (for SEM infection) or at least 21 days (for CNS or disseminated disease). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Acyclovir therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INVESTIGATIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigative therapies for neonatal herpes simplex virus (HSV) disease include human and humanized monoclonal antibodies directed against HSV gB and gD glycoproteins. These therapies have been beneficial in animal models of HSV disease. Studies in humans have shown that high titers of neutralizing antibodies protect neonates following perinatal HSV exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2\">",
"     2",
"    </a>",
"    ]. At present, antibody therapy for treatment or prevention of neonatal HSV is limited by the lack of an HSV hyperimmune globulin preparation and the variable amount of anti-HSV antibodies in intravenous immune globulin preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      as the antiviral agent of choice for the treatment of neonatal herpes simplex virus (HSV) infection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The dose is 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously divided every eight hours for all forms of neonatal HSV. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acyclovir therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      should be administered at the time neonatal HSV is suspected and continued pending results of clinical, laboratory, and imaging evaluations. Clinical features suggestive of HSV infection include mucocutaneous vesicles, seizures, aseptic meningitis, lethargy, respiratory distress, pneumonitis, thrombocytopenia, coagulopathy, hypothermia, hepatitis, sepsis-like illness, and elevated transaminases (",
"      <a class=\"graphic graphic_figure graphicRef67814 \" href=\"mobipreview.htm?3/42/3758\">",
"       figure 1",
"      </a>",
"      ). Some experts recommend empiric treatment for all sick neonates with fever or aseptic meningitis until results of HSV workup is known. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A comprehensive laboratory evaluation for HSV should be performed before initiation of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      therapy for neonatal HSV infection depends upon the pattern of illness and response to therapy. Localized skin, eye, and mouth (SEM) disease should be treated for a",
"      <strong>",
"       minimum",
"      </strong>",
"      of 14 days. Disseminated and central nervous system (CNS) disease should be treated for a",
"      <strong>",
"       minimum",
"      </strong>",
"      of 21 days. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonates with ocular HSV involvement should receive a topical ophthalmic solution (eg, 1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/47/43762?source=see_link\">",
"       trifluridine",
"      </a>",
"      , 0.1 percent iododeoxyuridine, or 3 percent vidarabine) in addition to systemic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      therapy and consultation with an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment of HSV eye disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      suppressive therapy for six months immediately following parenteral acyclovir for neonatal herpes simplex virus (HSV) disease, including skin, eye, and mouth disease; central nervous system disease; and disseminated HSV disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Suppressive therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strategies for prevention of intrauterine and perinatally acquired HSV infection are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link&amp;anchor=H14708541#H14708541\">",
"       \"Genital herpes simplex virus infection and pregnancy\", section on 'Pregnancy management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of postnatal transmission of HSV can be minimized by counseling family members with HSV lesions (cold sores, herpetic whitlow, herpetic gingivostomatitis) to avoid close contact with and kissing the newborn infant. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonates with perinatal exposure to HSV should be monitored for clinical evidence of HSV infection. Neonates who develop clinical evidence of HSV infection should undergo full virologic evaluation and be started on intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link&amp;anchor=H14#H14\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Laboratory evaluation'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Acyclovir therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation and management of asymptomatic neonates who are exposed to HSV during delivery depends upon the mother&rsquo;s history of genital HSV, maternal serologies for type specific HSV (if available), and the presence or absence of HSV genital lesions at the time of delivery. All such infants should be monitored for evidence of HSV infection (eg, skin or scalp rashes, conjunctival lesions, irritability, sepsis, etc (",
"      <a class=\"graphic graphic_figure graphicRef67814 \" href=\"mobipreview.htm?3/42/3758\">",
"       figure 1",
"      </a>",
"      )) during the first six weeks of life. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management of the asymptomatic exposed infant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/1\">",
"      Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003; 289:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/2\">",
"      Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev 2004; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/3\">",
"      Caviness AC, Demmler GJ, Swint JM, Cantor SB. Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates. Arch Pediatr Adolesc Med 2008; 162:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/4\">",
"      Davis KL, Shah SS, Frank G, Eppes SC. Why are young infants tested for herpes simplex virus? Pediatr Emerg Care 2008; 24:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/5\">",
"      Ambroggio L, Lorch SA, Mohamad Z, et al. Congenital anomalies and resource utilization in neonates infected with herpes simplex virus. Sex Transm Dis 2009; 36:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/6\">",
"      Nagamori T, Koyano S, Asai Y, et al. Sequential changes in pathophysiology of systemic inflammatory response in a disseminated neonatal herpes simplex virus (HSV) infection. J Clin Virol 2012; 53:265.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Herpes simplex. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/8\">",
"      Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/9\">",
"      Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991; 324:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/10\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/11\">",
"      Jones CA, Walker KS, Badawi N. Antiviral agents for treatment of herpes simplex virus infection in neonates. Cochrane Database Syst Rev 2009; :CD004206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/12\">",
"      Shah SS, Aronson PL, Mohamad Z, Lorch SA. Delayed acyclovir therapy and death among neonates with herpes simplex virus infection. Pediatrics 2011; 128:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/13\">",
"      Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/14\">",
"      Long SS. In defense of empiric acyclovir therapy in certain neonates. J Pediatr 2008; 153:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/15\">",
"      Kimberlin DW. When should you initiate acyclovir therapy in a neonate? J Pediatr 2008; 153:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/16\">",
"      Long SS, Pool TE, Vodzak J, et al. Herpes simplex virus infection in young infants during 2 decades of empiric acyclovir therapy. Pediatr Infect Dis J 2011; 30:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/17\">",
"      Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol 2007; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/18\">",
"      Mej&iacute;as A, Bustos R, Ardura MI, et al. Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis. J Perinatol 2009; 29:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/19\">",
"      Kimura H, Futamura M, Kito H, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991; 164:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/20\">",
"      Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J Pediatr 1993; 123:376.",
"     </a>",
"    </li>",
"    <li>",
"     Sanchez PJ, Demmler-Harrison GJ. Viral infections of the fetus and neonate. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.895.",
"    </li>",
"    <li>",
"     Cantey J, Wallihan R, Spicer K, et al. Persistent Herpes Simplex Virus (HSV) DNAemia in Neonatal HSV Infection: What&rsquo;s the Outcome? (abstract) ID Week San Diego 2012 https://idsa.confex.com/idsa/2012/webprogram/Paper35939.html (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     Schiffer JT, Melvin A, Mohan K, et al. Dynamics of Herpes Simplex Virus in Plasma in Neonates During Treatment (abstract). ID Week, San Diego 2012. https://idsa.confex.com/idsa/2012/webprogram/Paper36935.html (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/24\">",
"      Fonseca-Aten M, Messina AF, Jafri HS, S&aacute;nchez PJ. Herpes simplex virus encephalitis during suppressive therapy with acyclovir in a premature infant. Pediatrics 2005; 115:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/25\">",
"      Kimberlin D, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/26\">",
"      Whitley RJ, Nahmias AJ, Soong SJ, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980; 66:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/27\">",
"      Kimberlin DW, Whitley RJ, Wan W, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 2011; 365:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/28\">",
"      Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health Syst Pharm 1999; 56:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/29\">",
"      Bomgaars L, Thompson P, Berg S, et al. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer 2008; 51:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/30\">",
"      Kimberlin DW, Jacobs RF, Weller S, et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin Infect Dis 2010; 50:221.",
"     </a>",
"    </li>",
"    <li>",
"     Current Drug Shortages. US Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     Shortage of intravenous acyclovir. Red Book Online Special Alert - November 28, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/33\">",
"      Kimberlin DW. Ganciclovir may be used during intravenous acyclovir shortage. AAP News 2009; 30:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/34\">",
"      Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001; 108:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/35\">",
"      Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991; 324:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/36\">",
"      Verma A, Dhawan A, Zuckerman M, et al. Neonatal herpes simplex virus infection presenting as acute liver failure: prevalent role of herpes simplex virus type I. J Pediatr Gastroenterol Nutr 2006; 42:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/37\">",
"      Twagira M, Hadzic N, Smith M, et al. Disseminated neonatal herpes simplex virus (HSV) type 2 infection diagnosed by HSV DNA detection in blood and successfully managed by liver transplantation. Eur J Pediatr 2004; 163:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/38\">",
"      Egawa H, Inomata Y, Nakayama S, et al. Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: A case report of successful treatment with liver transplantation and perioperative acyclovir. Liver Transpl Surg 1998; 4:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/39\">",
"      Westerberg BD, Atashband S, Kozak FK. A systematic review of the incidence of sensorineural hearing loss in neonates exposed to Herpes simplex virus (HSV). Int J Pediatr Otorhinolaryngol 2008; 72:931.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Transmission of infectious agents via human milk. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.128.",
"    </li>",
"    <li>",
"     Gutierrez KM, Whitley RJ, Arvin AM. Herpes simplex virus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.813.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/42\">",
"      Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009; 361:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/43\">",
"      Overall JC Jr. Empiric therapy with acyclovir for suspected neonatal herpes simplex infection. Pediatr Infect Dis J 1989; 8:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/44\">",
"      Overall JC Jr. Herpes simplex virus infection of the fetus and newborn. Pediatr Ann 1994; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/45\">",
"      Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992; 15:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/46\">",
"      Scott LL. Perinatal herpes: current status and obstetric management strategies. Pediatr Infect Dis J 1995; 14:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40713/abstract/47\">",
"      Kimberlin DW, Baley J, Committee on infectious diseases, Committee on fetus and newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013; 131:e635.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6040 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40713=[""].join("\n");
var outline_f39_48_40713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Supportive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACYCLOVIR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239728820\">",
"      2012 IV ACYCLOVIR SHORTAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF HSV EYE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CNS disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Skin, eye, and mouth disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cutaneous recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Suppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LONG-TERM FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT OF THE ASYMPTOMATIC EXPOSED INFANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421546997\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421547421\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H570590993\">",
"      Maternal history of HSV, no active lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H510233438\">",
"      Maternal history of HSV, active lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H510233446\">",
"      No maternal history of HSV, active lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INVESTIGATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6040|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/42/3758\" title=\"figure 1\">",
"      Neonatal HSV SSx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6040|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/3/4159\" title=\"picture 1A\">",
"      Neonatal HSV neck vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/29/39382\" title=\"picture 1B\">",
"      Neonatal HSV scalp vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/44/28367\" title=\"picture 1C\">",
"      Neonatal HSV eye vesicles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/63/10235\" title=\"table 1\">",
"      Designation of genital HSV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=related_link\">",
"      Herpetic gingivostomatitis in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_48_40714="Treatment of diabetic nephropathy";
var content_f39_48_40714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of diabetic nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/48/40714/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/48/40714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic nephropathy, classically defined by the presence of proteinuria (macroalbuminuria, or \"severely increased albuminuria\" in the new nomenclature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/1\">",
"     1",
"    </a>",
"    ]), is a common problem that is most likely to occur in patients who have worse glycemic control, hypertension, glomerular hyperfiltration or a genetic predisposition. The lifetime risk of nephropathy is roughly equivalent in type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The earliest clinical manifestation of renal involvement in diabetes is an increase in albumin excretion (microalbuminuria, or \"moderately increased albuminuria\" in the new nomenclature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/1\">",
"     1",
"    </a>",
"    ]), a stage at which renal histology may be relatively normal or may reveal glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, regression of moderately increased albuminuria to normoalbuminuria occurs spontaneously in a substantial proportion of patients with type 1 and type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proteinuria in diabetes mellitus is occasionally due to a glomerular disease other than diabetic nephropathy. The major clinical clues suggesting nondiabetic glomerular disease are onset of proteinuria less than five years from the documented onset of diabetes in type 1 diabetes, acute onset of renal disease, presence of an active urine sediment containing red cells (particularly acanthocytes) and cellular casts, and in type 1 diabetes, the absence of diabetic retinopathy or neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of diabetic nephropathy\", section on 'Nondiabetic renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will address the treatment of diabetic nephropathy, particularly the importance of glycemic control and of rigorous antihypertensive therapy, with emphasis on the use of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. In addition to data from controlled trials, further proof of benefit from these therapies is the observation that the incidence of end-stage renal disease among patients with type 1 diabetes may be decreasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of strict glycemic control depends in part upon the stage at which it is begun and the degree of normalization of glucose metabolism; the evidence is best established in type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reviewed briefly, intensive insulin therapy has the following benefits with respect to the kidney:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can partially reverse the glomerular hypertrophy and hyperfiltration (both in the basal state and after a protein load) that are thought to be important risk factors for glomerular injury.",
"     </li>",
"     <li>",
"      It can delay the development of elevated albumin excretion (",
"      <a class=\"graphic graphic_figure graphicRef73143 \" href=\"mobipreview.htm?18/21/18781\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. Intensive therapy to near-normal glycemia reduces the onset or progression of diabetic nephropathy for years after less intensive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It can stabilize or decrease protein excretion in patients with increased albumin excretion, although this effect may not be apparent until relative normoglycemia has been maintained for two years. Furthermore, the restoration of euglycemia with pancreas transplantation in patients with type 1 diabetes prevents recurrent nephropathy in a renal allograft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies suggest that strict glycemic control may also slow the rate of progressive renal injury even after overt dipstick-positive proteinuria has developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Eight patients in whom pancreatic transplantation was successfully performed underwent serial renal biopsies at zero, five, and ten years posttransplant. All patients had functioning grafts at all time points; prior to transplant, three patients had normal albumin excretion, three had moderately increased albuminuria (formerly, microalbuminuria), and two had overt proteinuria.",
"   </p>",
"   <p>",
"    Transplantation stabilized but did not improve glomerular structure at five year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the following benefits were observed at ten years (",
"    <a class=\"graphic graphic_figure graphicRef67651 \" href=\"mobipreview.htm?29/43/30384\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesangial volume and mesangial matrix volume were significantly decreased as compared to the same measurements at zero and five years.",
"     </li>",
"     <li>",
"      In some patients, the width of the glomerular and tubular basement membranes and the mesangial volumes had returned to normal, and nodular glomerular lesions had disappeared.",
"     </li>",
"     <li>",
"      Tubular atrophy appeared improved, possibly due to reabsorption of diseased nephrons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN INHIBITION FOR PRIMARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their efficacy in diabetic patients with moderately increased albuminuria (formerly, microalbuminuria) or overt diabetic nephropathy (severely increased albuminuria, formerly macroalbuminuria) as described below, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers have been evaluated for efficacy in the primary prevention of diabetic nephropathy. The relevant data are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link&amp;anchor=H21#H21\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Primary prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link&amp;anchor=H18#H18\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ROLE OF OTHER FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to strict glycemic control, other factors contribute to glomerular injury in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of diabetic nephropathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extensive studies in diabetic animals suggest that intraglomerular hypertension and glomerular hypertrophy play an important role, being present early in the disease (as diabetes induces renal vasodilation and often a rise in glomerular filtration rate) and then being exacerbated by the compensatory response to nephron loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22484?source=see_link\">",
"     \"Mechanisms of glomerular hyperfiltration in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, reducing the intraglomerular pressure with dietary protein restriction or antihypertensive therapy with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), or the prevention of intraglomerular hypertension because of concurrent renal artery stenosis can minimize progression of or even prevent glomerular disease in the absence of glycemic control (",
"    <a class=\"graphic graphic_picture graphicRef64632 \" href=\"mobipreview.htm?11/8/11399\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Furthermore, ACE inhibition was more effective than triple therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    both in lowering the intraglomerular pressure and in minimizing glomerular injury (",
"    <a class=\"graphic graphic_figure graphicRef53771 \" href=\"mobipreview.htm?14/48/15117\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transforming growth factor beta (TGF-beta) may contribute to both the cellular hypertrophy and enhanced collagen synthesis that are seen in diabetic nephropathy. Inhibition of TGF-beta appears to ameliorate diabetic nephropathy in experimental models of diabetes and in preliminary human studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of diabetic nephropathy\", section on 'Cytokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experimental studies suggest that the non-dihydropyridine calcium channel blockers (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ) can slow the rate of progression of most of the morphologic features of diabetic renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/24\">",
"     24",
"    </a>",
"    ]. However, diltiazem alone was associated with increased tubulointerstitial fibrosis and global (not segmental) glomerulosclerosis; this effect was prevented by combined therapy with an ACE inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PPAR-gamma agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peroxisome proliferator-activated receptors (PPAR), which are ligand-activated transcription factors, appear to have a role in regulating adipogenesis, lipid metabolism, insulin sensitivity, inflammation, and blood pressure. They may also have a role in the development of nephropathy in type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PPAR-gamma agonists, such as the thiazolidinediones (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ) are used to lower the blood glucose in patients with type 2 diabetes. They also appear to have a variety of beneficial effects in animal models of diabetic nephropathy, such as reductions in fibrosis, mesangial cell proliferation, and inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the human data on outcomes are limited, PPAR-gamma agonists reduce urinary albumin excretion at various stages of nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/29-31\">",
"     29-31",
"    </a>",
"    ] and to reduce blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/31\">",
"     31",
"    </a>",
"    ]. Larger studies of longer duration are required to detect a renoprotective effect of these agents. A post hoc analysis of the PROACTIVE trial also failed to show a definitive benefit on cardiovascular risk reduction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    in people with stage 3 or higher nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRESERVATION OF RENAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is now clear evidence that antihypertensive therapy (particularly with an ACE inhibitor) and perhaps protein restriction can reduce the rate of progression in patients with type 1 diabetes and overt nephropathy.",
"   </p>",
"   <p>",
"    In patients with type 2 diabetes and overt diabetic nephropathy, more data are currently available on the preferential renoprotective efficacy of angiotensin receptor blockers (ARBs). However, ACE inhibitors appear to have a similar benefit.",
"   </p>",
"   <p>",
"    The efficacy of blood pressure and proteinuria reduction in patients with diabetic nephropathy is similar to that seen in patients with nondiabetic proteinuric chronic kidney disease (CKD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Type 1 diabetes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of antihypertensive therapy with an ACE inhibitor in type 1 diabetes can be demonstrated early in the course of the disease when moderately increased albuminuria (formerly called microalbuminuria) is the only clinical manifestation. In one study, for example, the administration of an ACE inhibitor to normotensive type 1 diabetics with moderately increased albuminuria decreased both albumin excretion and, at two years, progression to overt diabetic nephropathy when compared with patients treated with placebo (",
"    <a class=\"graphic graphic_figure graphicRef80409 \" href=\"mobipreview.htm?13/50/14125\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more pronounced benefit was demonstrated in the largest trial to date in type 1 diabetic patients who already had overt nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Four hundred nine patients with overt proteinuria and a plasma creatinine concentration &le;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (220",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    were randomly assigned to therapy with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    or placebo. Further antihypertensive drugs were then added as necessary, although calcium channel blockers and other ACE inhibitors were excluded.",
"   </p>",
"   <p>",
"    At approximately four years of nearly equivalent blood pressure control, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    had a slower rate of increase in the plasma creatinine concentration and a lesser likelihood of progressing to end-stage renal disease or death (",
"    <a class=\"graphic graphic_figure graphicRef60878 \" href=\"mobipreview.htm?28/22/29037\">",
"     figure 5",
"    </a>",
"    ). This benefit was limited to patients with an initial plasma creatinine concentration &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in whom that rate of rise in the plasma creatinine concentration was reduced by over 50 percent from 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per year (123",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in the placebo group to 0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per year (53",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    with captopril. In comparison, no improvement could be demonstrated in the patients with a lower baseline plasma creatinine concentration because the rate of progression was very slow in this group, with the plasma creatinine concentration rising by only 0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per year (9 to 18",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The beneficial response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , which was seen in both hypertensive and normotensive subjects, is consistent with smaller studies which suggested that antihypertensive therapy, particularly with an ACE inhibitor, slowed the rate of progression in diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Reducing blood pressure alone, especially to lower than",
"    <span class=\"nowrap\">",
"     120/75",
"    </span>",
"    mmHg, may be sufficient to slow the rate of progression of nephropathy, regardless of agent used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Remission or regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with type 1 diabetes have a marked antiproteinuric effect with sustained long-term remission or regression of nephropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the nephrotic syndrome; such patients appear to have a good renal outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the large randomized trial, 108 of 409 patients had nephrotic-range proteinuria, 40 of whom were randomly assigned to active therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      . At 7.7 years, six of these patients remained in clinical remission with substantially lower proteinuria (mean of 1",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours) and a stable plasma creatinine concentration (1.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [140",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second prospective study of 301 patients (of whom 271 were treated with antihypertensive medications and 30 were normotensive) evaluated the incidence of remission (defined as a decrease in albuminuria to below 200",
"      <span class=\"nowrap\">",
"       &micro;g/min",
"      </span>",
"      [288",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      for at least one year and a decrease in proteinuria of more than 30 percent) and regression (defined as a rate of decline in glomerular filtration rate of &le;1",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year) according to the degree of blood pressure control during a mean follow-up of seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/40\">",
"       40",
"      </a>",
"      ]. ACE inhibitors were the principal antihypertensive agents in 179 patients. Aggressive blood pressure control directly correlated with remission and regression, with the highest (mean arterial blood pressure of 113 mmHg) and lowest blood pressure quintiles (93 mmHg) associated with remission and regression rates of 17 and 7 percent and 58 and 42 percent, respectively.",
"     </li>",
"     <li>",
"      Among 126 patients with type 1 diabetes and nephrotic range proteinuria, 28 underwent sustained remission (defined as albuminuria &lt;600",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours for at least one year) after treatment with ACE inhibitors (21 patients) and non-ACE inhibitor medications (7 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/41\">",
"       41",
"      </a>",
"      ]. The average follow-up from the onset of nephrotic range proteinuria was nearly nine years. Compared to those who did not undergo remission, the rate of decline in GFR was markedly slower in those who underwent remission (3.8 versus 7.5",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/41\">",
"       41",
"      </a>",
"      ]. In a subsequent follow-up study (average remission period 5.5 years [1 to 22 years]), the remission group had a significantly lower risk of dialysis, transplantation, or death (RR 0.28) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, among patients with diabetic nephropathy due to type 1 diabetes mellitus, including some with advanced disease, remission or regression may occur with aggressive control of systemic blood pressure, particularly with ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to monotherapy with an ACE inhibitor or an angiotensin receptor blocker (ARB) alone, combined therapy with both an ACE inhibitor and an ARB given together may produce a greater reduction in protein excretion, a surrogate marker for renoprotection (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Effect on protein excretion'",
"    </a>",
"    below). In two short-term (8 week) studies in patients with type 1 diabetes, combination therapy resulted in superior reduction in albuminuria and blood pressure versus that observed with monotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, the proteinuria benefit may have been due to better blood pressure response with the combined therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been much less information on the effect of antihypertensive therapy with ACE inhibitors in patients with nephropathy due to type 2 diabetes, although a similar benefit appears to be present. More data are currently available on the efficacy of angiotensin receptor blockers (ARBs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict blood pressure control is important for preventing progression of diabetic nephropathy and other complications in patients with type 2 diabetes, but the optimal lower limit for systolic blood pressure is unclear. In the United Kingdom Prospective Diabetes Study (UKPDS), each 10 mmHg reduction in systolic pressure was associated with a 12 percent risk reduction in diabetic complications (P&lt;0.001); the lowest risk occurred at a systolic pressure below 120 mmHg (",
"    <a class=\"graphic graphic_figure graphicRef77963 \" href=\"mobipreview.htm?26/52/27469\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/46\">",
"     46",
"    </a>",
"    ]. However, these epidemiologic observations do not prove causality.",
"   </p>",
"   <p>",
"    In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    Diabetic Nephropathy Trial (IDNT, which is described below), progressively lower achieved systolic blood pressure to a threshold of 120 mmHg was associated with decreased cardiovascular death and heart failure (but not myocardial infarction), and a decreased risk of doubling of the serum creatinine concentration or progression to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a reduction of systolic blood pressure below 120 mmHg increased the risk of all-cause and cardiovascular death, as well as heart failure in the IDNT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/47\">",
"     47",
"    </a>",
"    ]. There was also a trend for increased adverse cardiovascular outcomes, including all-cause mortality, with diastolic blood pressures below 85 mmHg.",
"   </p>",
"   <p>",
"    A potential explanation for these findings is that a significantly higher proportion of patients in the group that achieved a systolic blood pressure below 120 mmHg had a history of heart disease or heart failure, but the number of patients was too small to determine whether the effect of low blood pressure was independent of the prior history of cardiovascular disease. Given these limitations, these findings are insufficient to warrant changing our recommendations concerning goal blood pressure.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Renal protection with ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major trials have demonstrated a clear benefit in terms of renoprotection with ARBs in patients with overt nephropathy due to type 2 diabetes. These trials compared ARBs to placebo or other drugs but not ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"       Irbesartan",
"      </a>",
"      Diabetic Nephropathy Trial (IDNT), 1715 hypertensive patients with nephropathy (mean serum creatinine 1.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [150",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      due to type 2 diabetes were randomly assigned to irbesartan (300",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. At 2.6 years, irbesartan was associated with a risk of the combined end point (doubling of the plasma creatinine, development of end-stage renal disease, or death from any cause) that was 23 and 20 percent lower than with amlodipine and placebo, respectively (",
"      <a class=\"graphic graphic_figure graphicRef80116 \" href=\"mobipreview.htm?17/60/18382\">",
"       figure 7",
"      </a>",
"      ); the values were 37 and 30 percent lower for doubling of the plasma creatinine. These benefits were independent of the differences in the magnitude of blood pressure reduction among the groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/47,48\">",
"       47,48",
"      </a>",
"      ], and the renal outcomes were best at systolic pressures below 134 mmHg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the RENAAL trial, 1513 patients with type 2 diabetes and nephropathy (mean serum creatinine 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [168",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      (50 titrating up to 100 mg once daily) or placebo, both in addition to conventional antihypertensive therapy (but not ACE inhibitors) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/52\">",
"       52",
"      </a>",
"      ]. Compared to placebo, losartan reduced the incidence of a doubling of the plasma creatinine by 25 percent and end-stage renal disease by 28 percent; the mean follow-up was 3.4 years. These benefits were again not associated with differences in blood pressure levels between the groups.",
"      <br/>",
"      <br/>",
"      Subsequent analysis of the RENAAL trial found that the most significant risk factor for progressive kidney disease was the degree of proteinuria, both initially and after six months of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/53-55\">",
"       53-55",
"      </a>",
"      ]. Additional post-hoc evaluations of RENAAL revealed the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/56-59\">",
"       56-59",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Every 10 mmHg increase in the baseline systolic blood pressure was associated with an enhanced risk of end-stage renal disease or death of 6.7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lowering albuminuria within the first six months correlated with a decreased subsequent cardiovascular risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/57\">",
"       57",
"      </a>",
"      ]. There was an 18 percent decrease in risk of a cardiovascular event for every 50 percent decrease in the rate of albumin excretion.",
"     </li>",
"     <li>",
"      Within all categories of attained blood pressure, a larger reduction in albuminuria correlated with a progressively lower risk of end-stage renal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of baseline retinopathy was associated with a poor renal outcome (increased proteinuria, decreased GFR, and development of end-stage renal disease) and a higher risk of death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both studies showed that the ARB groups had significant reductions in the development of and subsequent hospitalization for heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/60\">",
"     60",
"    </a>",
"    ], neither study initially found significant cardiovascular",
"    <strong>",
"     mortality",
"    </strong>",
"    reduction or, in the IDNT trial, a decrease in the composite cardiovascular event rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/61\">",
"     61",
"    </a>",
"    ]. These ARB trials were underpowered and of too short duration to detect a possible cardiovascular effect, but post hoc analyses yielded further information. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Renal protection with ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors have been compared with placebo and with ARBs in two trials (ADVANCE and DETAIL) of patients with type 2 diabetes.",
"   </p>",
"   <p>",
"    The ADVANCE trial compared the use of a fixed combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/24/34183?source=see_link\">",
"     perindopril-indapamide",
"    </a>",
"    to placebo in over 11,000 patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/62\">",
"     62",
"    </a>",
"    ]. The mean baseline serum creatinine was 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (87",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and moderately increased albuminuria (formerly called microalbuminuria) was present in 26 percent. The details and results of this trial, which included macrovascular outcomes, are discussed separately. What follows is a summary of the renal benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'ADVANCE trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a mean of 4.3 years, the patients treated with active therapy had the following differences in renal parameters compared to those treated with placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant decrease in mean blood pressure",
"      <span class=\"nowrap\">",
"       (5.6/2.2",
"      </span>",
"      mmHg)",
"     </li>",
"     <li>",
"      A significant reduction in the rate of new onset of moderately increased albuminuria (19.6 versus 23.6 percent) and in the combined end point of new onset of moderately increased albuminuria, worsening of moderately increased albuminuria, or new onset or worsening of severely increased albuminuria (formerly, macroalbuminuria) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The renal benefits of active treatment were consistent across all subgroups, including those that started with the lowest baseline blood pressure (mean systolic pressure &lt;120 mmHg [median 113 mmHg]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/63\">",
"     63",
"    </a>",
"    ]. There was no significant difference between the groups in doubling of the serum creatinine or progression to end-stage renal disease.",
"   </p>",
"   <p>",
"    It is not possible to determine the degree to which the renal benefits in ADVANCE were due to the ACE inhibitor or to the lower blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DETAIL was a randomized controlled trial that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    to the ARB",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    in 250 patients with early nephropathy as defined by albuminuria (82 percent moderately increased albuminuria [formerly, microalbuminuria] and 18 percent severely increased albuminuria [formerly, macroalbuminuria] to a maximum of 1.4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and a baseline GFR (measured isotopically) of approximately 93",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/66\">",
"     66",
"    </a>",
"    ]. A greater fall in GFR of at least 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    at five years was predefined as suggesting a clinically significant difference between the groups.",
"   </p>",
"   <p>",
"    At five years, there was a smaller decline in GFR in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    that was not significant (14.9 versus 17.9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    ). Both groups had similar rates or findings for the secondary end points, which included annual changes in the GFR, blood pressure, serum creatinine, urinary albumin excretion, end-stage kidney disease, cardiovascular events, and mortality.",
"   </p>",
"   <p>",
"    Two limitations of the trial were that only 168 of the original 250 patients completed the trial and that only 20 percent had severely increased albuminuria. Nevertheless, the results are consistent with the conclusion that ACE inhibitors are at least as effective as ARBs in diabetic patients with moderately increased albuminuria.",
"   </p>",
"   <p>",
"    Given the available evidence, ACE inhibitors or ARBs appear to provide preferential renoprotection in patients with diabetic nephropathy. However, patients with type 2 diabetes and advanced kidney disease are likely to progress relentlessly to end-stage renal disease despite treatment with ACE inhibitors or ARBs, although more slowly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16004841\">",
"    <span class=\"h3\">",
"     Aliskiren plus angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    , a direct renin inhibitor, in combination with either an ACE inhibitor or ARB does",
"    <strong>",
"     not",
"    </strong>",
"    appear to preserve renal function and increases the risk of adverse events. This was shown in the multinational Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE trial), which randomly assigned 8561 diabetic patients with either preexisting renal or cardiovascular disease to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    aliskiren or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/67\">",
"     67",
"    </a>",
"    ]. At baseline, the majority of patients had nephropathy (59 percent had an albumin-to-creatinine ratio of 200",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    or greater, and 26 percent had an albumin-to-creatinine ratio between 20 and 199",
"    <span class=\"nowrap\">",
"     mg/g;",
"    </span>",
"    the mean estimated glomerular filtration rate (eGFR) was 57",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ); all patients were receiving an ACE inhibitor or ARB at baseline. After a median follow-up of 32.9 months, more patients in the aliskiren group reached the composite primary end point of end-stage renal disease, doubling of serum creatinine, renal death, cardiovascular death, cardiac arrest, heart failure, non-fatal myocardial infarction, or non-fatal stroke (18.3 versus 17.1 percent). The incidence of renal events (end-stage renal disease, renal death, or doubling of serum creatinine) was similar with aliskiren and placebo (6 versus 5.9 percent). Adverse events requiring cessation of randomized therapy (usually hyperkalemia) were significantly more frequent with aliskiren (13.2 versus 10.2 percent). Due to the lack of apparent benefit and higher risk of side effects, the trial was stopped early for futility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1254778\">",
"    <span class=\"h3\">",
"     Bardoxolone methyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bardoxolone methyl is an antioxidant inflammatory modulator that may also have prostaglandin-like effects. It has been beneficial in animal models of drug-induced or ischemic acute kidney injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link&amp;anchor=H20#H20\">",
"     \"Inflammation in renal insufficiency\", section on 'Management issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Bardoxolone Methyl Treatment: Renal Function in",
"    <span class=\"nowrap\">",
"     CKD/Type",
"    </span>",
"    2 Diabetes (BEAM) trial, 227 patients with type 2 diabetes and an estimated GFR (eGFR) between 20 and 45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    were randomly assigned to either placebo or one of three doses of bardoxolone methyl (25, 75, or 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/68\">",
"     68",
"    </a>",
"    ]. Bardoxolone methyl therapy at all three doses significantly increased eGFR at 52 weeks of follow-up by 6 to 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , while placebo therapy had no effect.",
"   </p>",
"   <p>",
"    However, enthusiasm for this novel therapy is tempered by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bardoxolone methyl therapy significantly increased albuminuria. Although the actual data on change in albuminuria were not provided, the change in albuminuria was significantly correlated with the change in eGFR (ie, larger increases in eGFR were associated with larger increases in albumin excretion). The increase in eGFR was seen within four weeks of initiation of therapy, and then decreased almost to baseline within four weeks of stopping therapy. The increase in eGFR may be mediated by an increase in intraglomerular hydrostatic pressure. Such a change may be deleterious since, as described above, reductions in intraglomerular pressure (accompanied by an acute rise in the serum creatinine) are thought to play a central role in the beneficial effects of ACE inhibitors and ARBs in patients with diabetic nephropathy.",
"     </li>",
"     <li>",
"      Bardoxolone methyl therapy significantly increased adverse events (primarily muscle spasms and nausea) in a dose-dependent manner. Because of these adverse effects, the percentage of patients still taking the randomly assigned dose of bardoxolone methyl at 52 weeks was 81, 42, and 25 percent, respectively, in the 25, 75, and 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      groups. Bardoxolone methyl also increased systolic blood pressure by 2 to 4 mmHg, although this was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a trial testing Bardoxolone methyl in patients with type 2 diabetes and eGFR between 15 and 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    (the BEACON trial) was terminated early due to a higher rate of mortality and serious adverse events in the Bardoxolone methyl group. Thus, this therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with diabetic nephropathy and moderately advanced CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Protein restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains uncertain whether dietary protein restriction slows the long-term decline in glomerular filtration rate in diabetic nephropathy. Two small controlled trials (35 and 19 patients with type 1 diabetes, respectively) demonstrated that protein (and phosphate) restriction (0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) slowed the rate of decline in GFR by 60 to 75 percent from, for example, approximately 12",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year to 3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year (",
"    <a class=\"graphic graphic_figure graphicRef50017 \" href=\"mobipreview.htm?15/13/15581\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different results were noted in a prospective randomized trial of 82 patients with type 1 diabetic nephropathy: the rate of decline in the GFR was similar with a low-protein (0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) or usual protein diet (3.8 and 3.9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/71\">",
"     71",
"    </a>",
"    ]. However, although the number of events was low, the incidence of death or the onset of end-stage renal disease was significantly reduced with protein restriction. The mechanism underlying this apparent benefit is unclear.",
"   </p>",
"   <p>",
"    There are at least two explanations for the relative lack of benefit of a low-protein diet on GFR in the last study compared to the two previous trials. First, the different in protein intake between the two groups was probably substantially less in the last trial (0.89 versus 1.02",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day). Second, blood pressure, albuminuria, and glycemia were aggressively and similarly controlled in both groups. Given that these factors are independent and significant risk factors for deterioration in GFR, the ability to detect subtle differences in the rate of decline due to protein restriction alone may have been masked.",
"   </p>",
"   <p>",
"    There are several potential problems associated with a low protein diet. In addition to difficulty with compliance due to concurrent fat and simple carbohydrate restriction, diabetics are at increased risk for protein malnutrition because the reduction in intake may be associated with enhanced protein breakdown induced by insulin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECT ON PROTEIN EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of proteinuria in glomerular disease tends to vary directly with the intraglomerular pressure. It was therefore proposed that a treatment-induced reduction in protein excretion (in the absence of a large fall in GFR) reflected a desirable decline in intraglomerular pressure, and would result in improved renal outcomes.",
"   </p>",
"   <p>",
"    There is now consensus that a decrease in protein excretion has predictive importance for improved renal outcomes. There is evidence in nondiabetic patients, for example, that those with more than a 50 percent reduction in protein excretion following antihypertensive therapy have a better long-term outcome than those with little or no reduction in protein excretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H19#H19\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'The proteinuric response as a predictor of outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     Captopril",
"    </a>",
"    -Diabetes study that was previously described suggested that these findings also apply to diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with nephrotic range proteinuria at baseline were evaluated according to whether they underwent remission after therapy (defined as mean protein excretion less than 1.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or did not remit. The remission group had a relatively stable GFR (70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at baseline and 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at final evaluation) while the nonremitters tended to progress (GFR 66",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at baseline and 38",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at final evaluation). The remission group also had better control of hypertension &mdash; blood pressure at final evaluation",
"    <span class=\"nowrap\">",
"     119/76",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     143/85",
"    </span>",
"    in nonremitters &mdash; a finding that could also have contributed to the better outcome.",
"   </p>",
"   <p>",
"    Subsequently, post-hoc analyses of multiple large studies in type 1 and 2 diabetes, such as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    Diabetic Nephropathy Trial (IDNT) and the RENAAL trials as well as meta-analyses, have shown that lowering proteinuria is associated with improved outcomes in patients with overt diabetic nephropathy and a decreased risk of end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/35,38,50-54,73,74\">",
"     35,38,50-54,73,74",
"    </a>",
"    ]. There appears to be a dose response relationship, with a greater reduction in proteinuria associated with greater reduction in risk of renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ACE inhibitor or ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibition or ARB therapy and dietary protein restriction lower protein excretion in diabetic patients with moderately increased albuminuria (formerly called microalbuminuria) (",
"    <a class=\"graphic graphic_figure graphicRef80409 \" href=\"mobipreview.htm?13/50/14125\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/33,34,75-77\">",
"     33,34,75-77",
"    </a>",
"    ] and in those with overt (dipstick-positive proteinuria) renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50-54,78-84\">",
"     50-54,78-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of an ACE inhibitor will also lower protein excretion in patients already being treated with agents such as a beta blocker and a thiazide diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/85\">",
"     85",
"    </a>",
"    ]. The trials that have evaluated the prognostic value of lowering protein excretion are described in detail above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Type 1 diabetes'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Type 2 diabetes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The association between antihypertensive therapy, decrease in protein excretion, and improved renal outcomes in diabetic nephropathy was illustrated in analyses of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    and RENAAL trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A post-hoc analysis of the IDNT reported that the risk for renal failure doubled with each doubling of baseline protein excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/51\">",
"       51",
"      </a>",
"      ]. With therapy, significantly lower levels of proteinuria at one year were obtained with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"       irbesartan",
"      </a>",
"      (41 percent average decrease) than with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      (11 percent) or control (16 percent). Although the reduction in proteinuria was significantly associated with decreased blood pressure, proteinuria reduction was more with the ARB for each decrement in blood pressure observed.",
"      <br/>",
"      <br/>",
"      With respect to renal outcomes at one year, a decrease in proteinuria by one-half with therapy lowered the overall risk of developing renal failure by one-half. In addition, for the same proportional reduction in protein excretion, the risk reduction for renal failure was significantly greater for irbesartan compared with amlodipine. With multivariate analysis, it was estimated that approximately one-third of the renoprotective effect associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      was due to proteinuria reduction in the first 12 months of therapy.",
"     </li>",
"     <li>",
"      In the first six months of the RENAAL trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      reduced albuminuria by 28 percent, while placebo was associated with a 4 percent increase in albuminuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/54\">",
"       54",
"      </a>",
"      ]. With post-hoc analysis, albuminuria reduction by one-half in the first six months was associated with a 36 percent decreased risk for the renal end point and 45 percent lower risk for the development of end-stage renal disease at follow-up. After accounting for lower blood pressures with antihypertensive therapy, decreased albuminuria with losartan accounted nearly all of the benefits with respect to the renal end point and approximately one-half of the decreased incidence of end-stage renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ACE inhibitor plus ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superiority of combination therapy with an ACE inhibitor and an ARB compared with either therapy alone in decreasing proteinuria has been established in both type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/44,86,87\">",
"     44,86,87",
"    </a>",
"    ]. However, combination therapy may be associated with worse renal outcomes than with monotherapy. In addition, combination therapy with an ACE inhibitor and ARB is associated with a higher incidence of adverse effects and, in the ONTARGET trial of 25,620 patients with vascular disease or diabetes, there was an almost significant increase in mortality with combined therapy compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Additional results from the ONTARGET trial are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H16#H16\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ONTARGET trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H21#H21\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the subset of 3163 patients from ONTARGET with diabetic kidney disease, combination therapy was associated with a nonsignificantly higher incidence of chronic dialysis or doubling of serum creatinine (5.3 versus 4.8 percent), and a similar death rate (2.3 versus 2.2 percent), as compared with monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/90\">",
"     90",
"    </a>",
"    ]. In addition, patients with diabetic kidney disease who received combination therapy had higher rates of acute kidney injury requiring dialysis (1.4 versus 0.8 percent), hyperkalemia (11.3 versus 7.8 percent), and hypotension (2.8 versus 1.9 percent). As a result, we do",
"    <strong>",
"     not",
"    </strong>",
"    use combination therapy with an ACE inhibitor and ARB in patients with diabetic nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ARB plus aliskiren",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first effective oral direct renin inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    , was approved by the United States Food and Drug Administration in March 2007. Aliskiren lowers blood pressure to a degree comparable to most other agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the AVOID trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    was associated with a significant 20 percent greater reduction in proteinuria compared to losartan alone, in the absence of a significantly greater effect on blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/91\">",
"     91",
"    </a>",
"    ]. The role of aliskiren in preventing progression of CKD is discussed above. (See",
"    <a class=\"local\" href=\"#H16004841\">",
"     'Aliskiren plus angiotensin inhibition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Aldosterone antagonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics have generally not been considered to have an antiproteinuric effect despite reductions in blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, aldosterone antagonists appear to reduce proteinuria when used alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/92\">",
"     92",
"    </a>",
"    ], and to have an additive effect on proteinuria when used in combination with an ACE inhibitor or an ARB in both type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/93-98\">",
"     93-98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further blood pressure reduction does not completely explain the beneficial effect. This was demonstrated in a placebo-controlled trial that included 81 patients with diabetes, hypertension, and albuminuria who were treated with a high dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/98\">",
"     98",
"    </a>",
"    ]. In addition to lisinopril, patients were randomly assigned",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or placebo. At 48 weeks, patients treated with spironolactone had a 34 percent decrease in urine albumin-to-creatinine ratio compared to placebo. Patients who received losartan had only a 17 percent decrease in the albumin-to-creatinine ratio, which was not significantly different from placebo. Clinic and ambulatory blood pressure, creatinine clearance, and glycemic control were not different among groups. Serum potassium was significantly higher in patients who received either spironolactone or losartan compared to placebo.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    (an aldosterone antagonist) has also been examined in a randomized trial of 268 patients with type 2 diabetes already treated with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/99\">",
"     99",
"    </a>",
"    ]. Compared with placebo, eplerenone therapy at a dose of 50 or 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with a significant reduction in urinary albumin excretion (40 to 50 versus &lt;10 percent). However, severe hyperkalemia (serum potassium &gt;6",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    occurred in 9 and 23 percent of patients receiving 50 and 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of eplerenone, respectively (compared with 12 percent of patients in the placebo group). The authors concluded that 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of eplerenone in combination with an ACE inhibitor provides an additive antiproteinuric effect, with the rate of hyperkalemia being similar to placebo.",
"   </p>",
"   <p>",
"    It should be noted that the estimated GFR of the patients in this study was 74",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . In clinical practice, the use of this combination of agents in patients with reduced GFR should only be undertaken with CAREFUL instructions for dietary potassium restriction and avoidance of NSAIDs and COX-2 inhibitors, and probably with concomitant kaliuretic diuretic therapy. The risk of hyperkalemia may possibly be lower with an ARB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no long term data regarding benefit with the combination of ACE inhibitor or ARB and aldosterone blockade in terms of slowing the rate of loss of GFR. The risk of inducing or aggravating hyperkalemia in patients with long-standing diabetic nephropathy may limit the use of aldosterone antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other antihypertensive drugs and combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the other antihypertensive drugs, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    appear to be as consistently effective as an ACE inhibitor or ARB in lowering protein excretion in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/79-81,101\">",
"     79-81,101",
"    </a>",
"    ]. Furthermore, the antiproteinuric effects of verapamil and an ACE inhibitor may be additive. This was illustrated in a study of 30 patients with type 2 diabetes in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    or verapamil alone lowered protein excretion from 5.8 to 2.7",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/80\">",
"     80",
"    </a>",
"    ]. In comparison, using roughly one-half the dose of both drugs (mean of 16 mg of lisinopril and 187 mg of sustained-release verapamil) had a much greater antiproteinuric effect &mdash; 6.8 down to 1.7",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef57267 \" href=\"mobipreview.htm?23/48/24333\">",
"     figure 9",
"    </a>",
"    ). The low-dose combination regimen was also associated with fewer drug-induced side effects (such as constipation with verapamil and dizziness with lisinopril). A similar antiproteinuric advantage has been demonstrated with combination therapy with verapamil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef69411 \" href=\"mobipreview.htm?17/28/17870\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to a possible reduction in intraglomerular pressure, nondihydropyridine calcium channel blockers may have other protective actions. Some, but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/103\">",
"     103",
"    </a>",
"    ], studies in animals suggest that such calcium channel blockers may minimize progressive glomerular injury independent of a reduction in the intraglomerular pressure, perhaps by reducing the associated glomerular hypertrophy (",
"    <a class=\"graphic graphic_figure graphicRef72717 \" href=\"mobipreview.htm?6/36/6734\">",
"     figure 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/102\">",
"     102",
"    </a>",
"    ]. In humans, antiproteinuric effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    may also be due to improved glomerular size permselectivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations on the potential benefit of calcium channel blockers are of uncertain clinical relevance. These drugs were excluded in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    -diabetes trial noted above; as a result, their efficacy in the preservation of renal function in relation to ACE inhibitors has not yet been evaluated in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    in reducing protein excretion, the dihydropyridine calcium channel blockers (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , nitrendipine) have a variable effect ranging from increased protein excretion to no effect to a fall in protein excretion in different studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50,51,80-82,105-108\">",
"     50,51,80-82,105-108",
"    </a>",
"    ]. Beta-blockers have shown a variable response: the fall in protein excretion is generally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/78,81,101,109\">",
"     78,81,101,109",
"    </a>",
"    ], but not always [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/83\">",
"     83",
"    </a>",
"    ] substantially less than that induced by an ACE inhibitor or ARB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Salt intake and proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high salt intake has been shown to blunt the antiproteinuric effects of angiotensin inhibitors in patients with non-diabetic kidney disease. Salt restriction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diuretics enhance the effect of renin-angiotensin blockade on proteinuria in these patients (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fewer studies have also demonstrated this in patients with diabetic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. Thus, patients on ACE inhibitors or ARBs who do not have sufficient reduction in proteinuria despite appropriate blood pressure goals (eg, systolic blood pressure &lt;130) should be instructed to take a low sodium diet. An assessment of baseline sodium intake can be undertaken by obtaining a 24-hour urine for sodium and creatinine. This can be repeated after several months on the low sodium diet to determine the actual sodium intake if there is insufficient reduction in proteinuria.",
"   </p>",
"   <p>",
"    Salt restriction to &le;70",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    has been found to enhance the antiproteinuric effects of ARB in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/111\">",
"     111",
"    </a>",
"    ]. However this degree of restriction may be difficult to achieve and maintain, and we advocate restricting sodium intake to approximately &le;100",
"    <span class=\"nowrap\">",
"     meq/day.",
"    </span>",
"    The effects of salt intake and restriction on hypertension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a low sodium diet is not possible, administration of a diuretic partially corrects the loss of antiproteinuric effect due to a high sodium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other agents have been tried with the goal of reduction of proteinuria in diabetes and other proteinuric nephropathies. Of these, limited data, including a meta-analysis, suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    lowers proteinuria and may have similar antiproteinuric effects as ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/113\">",
"     113",
"    </a>",
"    ]. However, the quality of studies is poor. In addition, silymarin (an herbal drug with antioxidant properties used in patients with hepatic disease) was shown to reduce proteinuria in patients with diabetic nephropathy, although this trial was small, of short duration, and will need confirmation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other agents, some experimental and others in clinical use for other indications, have also been studied, including endothelin receptor antagonists, protein kinase C inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    (a peroxisome proliferator activated receptor (PPAR)-alpha specific ligand), sulodexide, pyridoxamine dihydrochloride, and fish oil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/115-125\">",
"     115-125",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Hyperlipidemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are insufficient data on any of these agents to advocate their use for the treatment or prevention of diabetic nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the aggregate, the above studies suggest that ACE inhibitors, ARBs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    have relatively unique beneficial effects on proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/81\">",
"     81",
"    </a>",
"    ]. The reduction in protein excretion may reflect both a fall in intraglomerular pressure and, at least with the ACE inhibitors, an apparent direct improvement in the size-selective properties of the glomerular capillary wall (via an uncertain mechanism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/126\">",
"     126",
"    </a>",
"    ]. The observation that protein excretion progressively declines over time is consistent with an effect on permselectivity, since the hemodynamic effects of ACE inhibition occur very rapidly and are then stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two final points deserve repeat emphasis. First, although accepted, it has yet to be clearly and directly proven that a fall in protein excretion in overt nephropathy is an indicator of a better long-term outcome in diabetic nephropathy. There is, however, a very strong association, as shown in observational, post-hoc analyses, and meta-analyses, between decreased proteinuria and slowing of progressive nephropathy and decreased risk of end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/35,38,50,52,54,73,74\">",
"     35,38,50,52,54,73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H19#H19\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'The proteinuric response as a predictor of outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second, proteinuria tends to increase over time in untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/34,75,76\">",
"     34,75,76",
"    </a>",
"    ]. Thus, those antihypertensive drugs that produce no or a lesser fall in protein excretion may still be having a beneficial effect when compared to the progressive course in untreated patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     WEIGHT REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked decreases in proteinuria may be observed in obese diabetics who lose weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/127\">",
"     127",
"    </a>",
"    ]. This was illustrated in a randomized trial of 30 overweight patients (body mass index &gt;27",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    with proteinuric nephropathy, 14 of whom had type 2 diabetes; proteinuria significantly decreased at five months among dieters versus the non-dieters control group (31 percent decrease versus a slight increase) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/127\">",
"     127",
"    </a>",
"    ]. A mean weight loss of four percent was observed in the diet group. Although no significant differences in renal function were reported in either group, the length of follow-up was probably too short to have observed such an effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HYPERLIPIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia is common in diabetic patients, a tendency that is increased by the development of renal insufficiency. Aggressive lipid lowering is an important part of the medical management of all diabetic patients, since diabetes is considered a coronary heart disease equivalent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to promoting systemic atherosclerosis, an elevation in lipid levels also may contribute to the development of glomerulosclerosis in chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Hyperlipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The applicability of these findings to diabetic nephropathy is uncertain. A prospective study in patients with type 1 diabetes mellitus found that a plasma cholesterol concentration above 220",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was an important risk factor for progressive renal disease, particularly if the diastolic pressure were also above 85 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/128\">",
"     128",
"    </a>",
"    ]. In addition, lipid lowering (at least with statins) may slow the rate of progression of chronic kidney disease, including diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link\">",
"     \"Statins and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of data concerning the effects of lipid lowering alone in terms of preventing diabetic nephropathy. Among 314 participants in the Diabetes Atherosclerosis Intervention Study, all but three patients with type 2 diabetes had either normal albuminuria (214 patients) or moderately increased albuminuria (formerly called microalbuminuria) (97) prior to being randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/115\">",
"     115",
"    </a>",
"    ]. In a post-hoc analysis, worsening of proteinuria was significantly less with active therapy. Most prominently, the rate of progression from normal albumin excretion to moderately increased albuminuria at three years was significantly lower with fenofibrate (3 of 101 versus 20 of 113 for placebo).",
"   </p>",
"   <p>",
"    Possible mechanisms of benefit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    include suppression of inflammation and decreased production of type 1 collagen in mesangial cells. These effects may be related to increased activity of PPAR (peroxisome proliferator-activated receptor)-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intensive combined therapy, including lipid lowering, is likely to be the optimal therapeutic approach to patients with diabetic nephropathy (including those moderately increased albuminuria). This was perhaps best shown in the Steno-2 studies of patients with type 2 diabetes. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Combined therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMBINED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapeutic approach to the treatment of diabetic nephropathy may be intensive combined therapy, thereby targeting the many factors underlying the disease, including hyperglycemia, hypertension, and dyslipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of early, intensive, combined therapy was evaluated in an uncontrolled study of 13 patients with type 1 diabetes mellitus, who, at baseline, had a mean glomerular filtration rate of 58",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and mean albumin excretion of about 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/132\">",
"     132",
"    </a>",
"    ]. Treatment consisted of an intensive insulin regimen (which lowered the hemoglobin A1c concentration from 8.7 to 6.5 percent), dietary protein restriction, and antihypertensive therapy with an ACE inhibitor (which lowered the blood pressure to",
"    <span class=\"nowrap\">",
"     120/75).",
"    </span>",
"    At the end of three years, the glomerular filtration rate had increased to 84",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and albumin excretion had fallen to 92",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    potential efficacy of intensive combined therapy in patients with type 2 diabetes and moderately increased albuminuria (formerly called microalbuminuria) was examined in the Steno type 2 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. In this prospective study, 160 patients were randomly assigned to standard or multifactorial intensive therapy. The intensive regimen consisted of behavioral therapy (including advice concerning diet, exercise, and smoking cessation) and pharmacologic intervention (consisting of the administration of an ACE inhibitor and multiple other agents to attain several aggressive therapeutic goals) (",
"    <a class=\"graphic graphic_table graphicRef69810 \" href=\"mobipreview.htm?5/1/5148\">",
"     table 1",
"    </a>",
"    ). The primary end point was progression to overt nephropathy at four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/133\">",
"     133",
"    </a>",
"    ] and a composite cardiovascular end point at eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a mean follow-up of 7.8 years, intensive therapy reduced both microvascular and macrovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/134\">",
"     134",
"    </a>",
"    ]. With respect to diabetic nephropathy, there were significant improvements in albumin excretion (-20 versus +30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and in progression to overt nephropathy, defined as urine albumin excretion greater than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 versus 39 percent, relative risk 0.39). In contrast, the glomerular filtration rate fell to the same degree in both groups (-30 versus -32",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ).",
"   </p>",
"   <p>",
"    The details of the protocol and overall results of this study are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, an aggressive combined approach may offer optimal protection against disease progression for patients with either type 1 and type 2 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/135,136\">",
"     135,136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24644?source=see_link\">",
"       \"Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of diabetic nephropathy continues to evolve. It now seems clear in type 1 diabetes that ACE inhibitors, as part of a therapeutic regimen to achieve blood pressure goals, both lower protein excretion and slow the rate of disease progression in patients with moderately increased albuminuria (the new nomenclature for what was formerly called microalbuminuria) and in those with severely increased albuminuria (the new nomenclature for what was formerly called macroalbuminuria or overt nephropathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/34,35,37,40,41\">",
"     34,35,37,40,41",
"    </a>",
"    ]; a similar effect is seen in type 2 diabetes with ARBs or ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50,52,66,137-139\">",
"     50,52,66,137-139",
"    </a>",
"    ]. The blood pressure and proteinuria goals are similar to those in patients with proteinuric nondiabetic chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to appreciate, however, that these agents slow the rate of progression, but do not stop progression (",
"    <a class=\"graphic graphic_figure graphicRef60878 \" href=\"mobipreview.htm?28/22/29037\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80116 \" href=\"mobipreview.htm?17/60/18382\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, other modalities are also required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/135\">",
"     135",
"    </a>",
"    ]. Probably most important is maintenance of strict blood pressure and glycemic control early in the course of the disease. In addition, dietary protein restriction may be beneficial in patients with established nephropathy and aggressive lipid lowering is likely to improve cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Measurement of protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally monitor protein excretion in patients with chronic renal failure by repeated measurement of the urine protein- or albumin- to-creatinine ratio every few months, using a first-morning void whenever feasible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal rate of albumin excretion is less than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     &micro;g/min);",
"    </span>",
"    persistent albumin excretion between 10 and 29",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (7 to 19",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    is called high normal albuminuria; persistent albumin excretion between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    is called moderately increased albuminuria (formerly called microalbuminuria) and, in patients with diabetes (particularly type 1 diabetes), is usually indicative of diabetic nephropathy (unless there is some coexistent renal disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/140\">",
"     140",
"    </a>",
"    ]. Values above 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    are considered to represent severely increased albuminuria (formerly called macroalbuminuria or overt nephropathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/141\">",
"     141",
"    </a>",
"    ]. Although these cutoffs defining normal albuminuria, high normal albuminuria, moderately increased albuminuria and severely increased albuminuria facilitate determining risk for progression of nephropathy, the risk of developing overt diabetic nephropathy is probably related to higher albumin excretion rates at all levels without arbitrary thresholds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 1 diabetes should probably be screened yearly (after the first five years) for the presence of moderately increased albuminuria (formerly called microalbuminuria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/142\">",
"     142",
"    </a>",
"    ]. Use of the albumin-to-creatinine ratio in an untimed urinary sample is recommended as the preferred screening strategy for all diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/143\">",
"     143",
"    </a>",
"    ]. Measurement of the serum creatinine concentration and estimation of the glomerular filtration rate should also be performed. An elevated albumin-to-creatinine ratio should be confirmed with at least two additional tests performed over the subsequent 3 to 6 months, with confirmation of the diagnosis requiring at least 2 of 3 positive samples. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link&amp;anchor=H20#H20\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that patients with type 1 diabetes and persistent moderately increased albuminuria be treated with strict glycemic and lipid control. An ACE inhibitor should be given to patients with blood pressures greater than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg. Among patients with lower pressures who are not given an ACE inhibitor, the albumin-to-creatinine ratio should be monitored at six to twelve month intervals and an ACE inhibitor begun if there is reproducible evidence of a clear increase in albumin excretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/6,144\">",
"     6,144",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations concerning treatment of normotensive patients with type 1 diabetes with and without persistent moderately increased albuminuria are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for moderately increased albuminuria (formerly called microalbuminuria) is not as useful in type 2 diabetes because it is not as predictive of progression to severely increased albuminuria (formerly called macroalbuminuria or overt nephropathy) as in type 1 diabetes. In many cases, moderately increased albuminuria is present at the time of diagnosis of diabetes. This most likely reflects delayed diagnosis of diabetes, but obesity and atherosclerosis may also account for moderately increased albuminuria. Nevertheless, the presence of moderately increased albuminuria is associated with an increased risk of developing cardiovascular disease, and most patients with moderately increased albuminuria have other reasons for therapy with an ACE inhibitor or ARB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/145\">",
"     145",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link&amp;anchor=H17#H17\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'Screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link&amp;anchor=H14#H14\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once severely increased albuminuria occurs, the rate of loss of GFR and the deleterious effect of hypertension are equivalent to that seen in type 1 diabetes, suggesting similar pathogenetic mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. In the absence of aggressive intervention, the time to progression from severely increased albuminuria to end-stage renal disease in either form of diabetes averages six to seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. Overall, a faster rate of decline in GFR is associated with higher levels of albuminuria, HgA1c, and systolic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal initial therapy of nephropathy in patients with type 2 diabetes is angiotensin inhibition. Although there are more data on the renoprotective effect of ARBs, ACE inhibitors can be also be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50,52,66,138,139\">",
"     50,52,66,138,139",
"    </a>",
"    ]. Since the goal blood pressure in patients with diabetes and those with proteinuric chronic kidney disease of any cause is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg, almost all patients with diabetic nephropathy will require additional agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/144\">",
"     144",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    can produce a further reduction in protein excretion, which may correlate with further protection against progression of the renal disease, while a loop diuretic is typically required in patients with edema or renal insufficiency. Despite the demonstrated beneficial effect on proteinuria, we recommend NOT using combined therapy with ACE inhibitors plus ARBs since no reliable study has demonstrated a long term beneficial effect on renal function with combined therapy, and there is an increase in adverse side effects, particularly mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/89,149\">",
"     89,149",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'ACE inhibitor plus ARB'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Therapeutic goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general aim with an ACE inhibitor or ARB in patients with diabetic nephropathy and proteinuria (at least 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is to reduce the blood pressure to less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg and perhaps to lower levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/144,150,151\">",
"     144,150,151",
"    </a>",
"    ]. Almost all patients require more than one drug to achieve this goal; in the UKPDS, for example, approximately 30 percent of patients were taking three or more drugs (",
"    <a class=\"graphic graphic_figure graphicRef58079 \" href=\"mobipreview.htm?40/53/41821\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/152\">",
"     152",
"    </a>",
"    ]. The goal blood pressure in patients with hypertension but not proteinuria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with underlying cardiovascular disease (prior MI, angina), diastolic blood pressure should probably not be allowed to go below 75 mmHg given concerns that lower blood pressures may be associated with a higher risk of coronary events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/47,56,153\">",
"     47,56,153",
"    </a>",
"    ]. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H10#H10\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Are lower blood pressures harmful?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the desired fall in intraglomerular pressure should also have a significant reduction in protein excretion and the degree of antiproteinuric response correlates with protection against disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Preservation of renal function'",
"    </a>",
"    above.) To achieve maximal antiproteinuric effects with ACE inhibitors, sodium intake must be restricted to less than 90",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if the pressure at which the maximum antiproteinuric response occurs represents the optimal pressure for protection against glomerular injury. Patients who underwent remission of proteinuria in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    -diabetes trial had a lower diastolic pressure (and less disease progression) than those who did not remit (76 versus 85 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/155\">",
"     155",
"    </a>",
"    ]. Similar observations have been made in nondiabetics with protein excretion above 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in whom lowering the blood pressure to approximately",
"    <span class=\"nowrap\">",
"     120/75",
"    </span>",
"    was associated with a slower rate of disease progression (",
"    <a class=\"graphic graphic_figure graphicRef78190 \" href=\"mobipreview.htm?16/53/17245\">",
"     figure 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further impetus for aggressive blood pressure lowering comes from the observation in UKPDS that each 10 mmHg reduction in systolic pressure was associated with a 12 percent risk reduction in total diabetic complications (p&lt;0.001); the lowest risk occurred at a systolic pressure below 120 mmHg (",
"    <a class=\"graphic graphic_figure graphicRef77963 \" href=\"mobipreview.htm?26/52/27469\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, the data for renal protection clearly support administration of an ACE inhibitor in patients with type 1 diabetes; an ARB can be given if the ACE inhibitor is limited by side effects (usually cough). Although there are more data on the renoprotective effect of ARBs in patients with nephropathy due to type 2 diabetes, in particular among patients with overt proteinuria, it is probable that ACE inhibitors are a reasonable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50,52,56,66\">",
"     50,52,56,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to monotherapy with an ACE inhibitor or ARB alone, combined therapy produced a greater reduction in protein excretion in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. On the other hand, combination therapy with an ACE inhibitor and ARB is associated with a higher incidence of adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In the ONTARGET trial, which comprised 25,620 patients with vascular disease or diabetes, there was an increase in adverse side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations for therapeutic goals are consistent with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    Clinical Practice Guidelines for diabetes and chronic kidney disease and the Guidelines on hypertension and antihypertensive agents in chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/6,143,144\">",
"     6,143,144",
"    </a>",
"    ]. Aggressive goals are recommended for both proteinuria and blood pressure. Antihypertensive therapy is given for both renal protection and cardiovascular protection, since chronic kidney disease and diabetes are independently associated with a marked increase in cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in protein excretion to less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      recognizing the difficulty of achieving such a goal in many patients, we recommend a minimum reduction of at least 60 percent of baseline values. Our renal goals related to moderately increased albuminuria (formerly called microalbuminuria) are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reduction in blood pressure to less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. Data from patients with nondiabetic proteinuric chronic kidney disease suggests that an even lower systolic pressure may be more effective in slowing progressive renal disease in patients with a spot urine total protein-to-creatinine ratio &ge;1000",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (which usually represents protein excretion of greater than 1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/144\">",
"       144",
"      </a>",
"      ]. This observation probably extends to those with diabetic nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Caution: The diastolic blood pressure should not be lowered below 75 mmHg in patients with active coronary disease, and the systolic blood pressure should not be lowered to below 110 mmHg in any patient.",
"      <br/>",
"      <br/>",
"      These aggressive goals will, in most patients, require therapy with multiple drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/157\">",
"       157",
"      </a>",
"      ]:",
"     </li>",
"     <li>",
"      It seems likely that ACE inhibitors and ARBs are equally effective in the treatment of diabetic nephropathy in patients with type 1 or 2 diabetic nephropathy. Nevertheless, we prefer initiating therapy with an ACE inhibitor in type 1 diabetic nephropathy and either an ACE inhibitor or an ARB in type 2 diabetic nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/66,144\">",
"       66,144",
"      </a>",
"      ]. We recommend NOT using combination therapy with ACE inhibitors and ARBs. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Therapeutic goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Almost all patients will require a diuretic to attain goal blood pressure. Because subclinical fluid overload can maintain hypertension in patients with CKD, the goal of diuretic therapy is to attain dry weight which, in the presence of persistent hypertension, is defined as the weight at which further fluid loss leads to symptoms (fatigue, orthostatic hypotension) or to decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the blood urea nitrogen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum creatinine concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of hypertension in acute and chronic kidney disease\", section on 'Choice of antihypertensive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If appropriate diuretic therapy plus either an ACE inhibitor or ARB does not achieve goal blood pressure, we suggest a nondihydropyridine calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ). However, these drugs should NOT be given in combination with a beta blocker. Thus, in patients already being treated with a beta blocker for another indication, we suggest adding a long-acting dihydropyridine calcium channel blocker.",
"     </li>",
"     <li>",
"      If the proteinuria goal is not reached after the blood pressure goal has been attained, we add a nondihydropyridine calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) if not already being used and if the patient is not being treated with a beta blocker.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two potential complications of ACE inhibitor or ARB therapy in patients with CKD are an initial fall in glomerular filtration rate and the development of hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial fall in glomerular filtration rate resulting in an elevation in serum creatinine is due to the associated reduction in glomerular capillary pressure. The rise in serum creatinine typically occurs early during dose titration. Late acute increases in serum creatinine (as opposed to gradual increases due to disease progression) can occur if diuretics are started or the dose is increased or if some other renal insult is superimposed, such as a nonsteroidal antiinflammatory drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/149\">",
"       149",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An elevation in serum creatinine of as much as 30 to 35 percent above baseline that stabilizes within the first two to four months of therapy is considered acceptable and not a reason to discontinue therapy with these drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/149,158\">",
"       149,158",
"      </a>",
"      ]. A review of 12 randomized trials of CKD progression found that patients with a limited early acute increase in serum creatinine after initiation of ACE inhibitors were more likely to have long-term preservation of kidney function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/149\">",
"       149",
"      </a>",
"      ]:",
"     </li>",
"     <li>",
"      Hyperkalemia due to removal of the angiotensin II-mediated stimulus to the release of aldosterone is most likely to occur in patients in whom the plasma potassium concentration is elevated or in the high normal range prior to therapy. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Because of the decline in renal function and a rise in plasma potassium that typically occur soon after the onset of therapy, a plasma creatinine and potassium should be measured within three to five days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Protein restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of dietary protein restriction is uncertain in diabetics, particularly in view of problems with compliance in patients already being treated with fat and simple carbohydrate restriction. Furthermore, it is uncertain if a low protein diet is significantly additive to other measures aimed at preserving renal function, such as ACE inhibition and aggressive control of blood pressure and blood glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/48/40714/abstract/71\">",
"     71",
"    </a>",
"    ]. It is reasonable, however, to avoid a high protein diet by limiting protein intake to a level at which compliance is not difficult for the patient (about 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/1\">",
"      KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3:19. file://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/2\">",
"      Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/3\">",
"      Chavers BM, Bilous RW, Ellis EN, et al. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989; 320:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/4\">",
"      Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/5\">",
"      Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/6\">",
"      Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/7\">",
"      Nishimura R, Dorman JS, Bosnyak Z, et al. Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. Am J Kidney Dis 2003; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/8\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/9\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/10\">",
"      Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 Suppl 2:B21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/11\">",
"      Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/12\">",
"      Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med 1989; 321:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/13\">",
"      Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1993; 342:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/14\">",
"      Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/15\">",
"      Fioretto P, Sutherland DE, Najafian B, Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/16\">",
"      Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005; 28:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/17\">",
"      Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/18\">",
"      Berkman J, Rifkin H. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson): report of a case. Metabolism 1973; 22:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/19\">",
"      Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/20\">",
"      Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 1999; 10:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/21\">",
"      Akahori H, Ota T, Torita M, et al. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005; 314:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/22\">",
"      Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006; 21:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/23\">",
"      Soma J, Sugawara T, Huang YD, et al. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002; 92:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/24\">",
"      Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/25\">",
"      Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/26\">",
"      Li Y, Wen X, Spataro BC, et al. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/27\">",
"      Weissgarten J, Berman S, Efrati S, et al. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats. Nephrol Dial Transplant 2006; 21:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/28\">",
"      Tang SC, Leung JC, Chan LY, et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol 2006; 17:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/29\">",
"      Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/30\">",
"      Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005; 68:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/31\">",
"      Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/32\">",
"      Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/33\">",
"      Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/34\">",
"      Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 1996; 39:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/35\">",
"      Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/36\">",
"      Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 1994; 46:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/37\">",
"      Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/38\">",
"      Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/39\">",
"      Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/40\">",
"      Hovind P, Rossing P, Tarnow L, et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/41\">",
"      Hovind P, Rossing P, Tarnow L, et al. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001; 24:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/42\">",
"      Hovind P, Tarnow L, Rossing P, et al. Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2004; 66:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/43\">",
"      Steffes MW. Affecting the decline of renal function in diabetes mellitus. Kidney Int 2001; 60:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/44\">",
"      Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/45\">",
"      Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/46\">",
"      Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/47\">",
"      Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/48\">",
"      Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/49\">",
"      Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/50\">",
"      Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/51\">",
"      Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/52\">",
"      Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/53\">",
"      Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/54\">",
"      de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/55\">",
"      Zhang Z, Shahinfar S, Keane WF, et al. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol 2005; 16:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/56\">",
"      Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/57\">",
"      de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/58\">",
"      Parving HH, Mogensen CE, Thomas MC, et al. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. QJM 2005; 98:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/59\">",
"      Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/60\">",
"      Remuzzi G, Ruggenenti P, Perna A, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/61\">",
"      Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/62\">",
"      Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/63\">",
"      de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/64\">",
"      Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE? Lancet 2007; 370:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/65\">",
"      Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med 2008; 148:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/66\">",
"      Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/67\">",
"      Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/68\">",
"      Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/69\">",
"      Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/70\">",
"      Walker JD, Bending JJ, Dodds RA, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/71\">",
"      Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/72\">",
"      Brodsky IG, Robbins DC, Hiser E, et al. Effects of low-protein diets on protein metabolism in insulin-dependent diabetes mellitus patients with early nephropathy. J Clin Endocrinol Metab 1992; 75:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/73\">",
"      Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/74\">",
"      Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/75\">",
"      Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/76\">",
"      Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45:S150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/77\">",
"      Bending JJ, Dodds RA, Keen H, Viberti GC. Renal response to restricted protein intake in diabetic nephropathy. Diabetes 1988; 37:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/78\">",
"      Bj&ouml;rck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/79\">",
"      Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/80\">",
"      Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/81\">",
"      B&ouml;hlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7:84S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/82\">",
"      Guasch A, Parham M, Zayas CF, et al. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997; 8:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/83\">",
"      Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/84\">",
"      Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/85\">",
"      Pedersen MM, Hansen KW, Schmitz A, et al. Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy. Kidney Int 1992; 41:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/86\">",
"      Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/87\">",
"      Song JH, Cha SH, Lee HJ, et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 2006; 21:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/88\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/89\">",
"      Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/90\">",
"      Mann JF, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens 2013; 31:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/91\">",
"      Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/92\">",
"      Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/93\">",
"      Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/94\">",
"      Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/95\">",
"      Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/96\">",
"      Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/97\">",
"      van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/98\">",
"      Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/99\">",
"      Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/100\">",
"      Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000; 58:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/101\">",
"      Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/102\">",
"      Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/103\">",
"      Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/104\">",
"      Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/105\">",
"      Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19:II237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/106\">",
"      Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/107\">",
"      Yasuda G, Ando D, Hirawa N, et al. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Diabetes Care 2005; 28:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/108\">",
"      Katayama K, Nomura S, Ishikawa H, et al. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006; 70:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/109\">",
"      Nielsen FS, Rossing P, Gall MA, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/110\">",
"      Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996; 125:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/111\">",
"      Houlihan CA, Allen TJ, Baxter AL, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/112\">",
"      Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/113\">",
"      McCormick BB, Sydor A, Akbari A, et al. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008; 52:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/114\">",
"      Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012; 60:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/115\">",
"      Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/116\">",
"      Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/117\">",
"      Rossing P, Hansen BV, Nielsen FS, et al. Fish oil in diabetic nephropathy. Diabetes Care 1996; 19:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/118\">",
"      Hagiwara S, Makita Y, Gu L, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant 2006; 21:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/119\">",
"      Heerspink HL, Greene T, Lewis JB, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/120\">",
"      Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/121\">",
"      Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/122\">",
"      Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/123\">",
"      Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/124\">",
"      Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/125\">",
"      Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007; 2:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/126\">",
"      Morelli E, Loon N, Meyer T, et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/127\">",
"      Morales E, Valero MA, Le&oacute;n M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/128\">",
"      Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994; 45:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/129\">",
"      Tonolo G, Velussi M, Brocco E, et al. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006; 70:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/130\">",
"      Park CW, Zhang Y, Zhang X, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/131\">",
"      Okopie B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/132\">",
"      Manto A, Cotroneo P, Marra G, et al. Effect of intensive treatment on diabetic nephropathy in patients with type I diabetes. Kidney Int 1995; 47:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/133\">",
"      Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/134\">",
"      Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/135\">",
"      Gerstein HC. Preventive medicine in a diabetes clinic: an opportunity to make a difference. Lancet 1999; 353:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/136\">",
"      Leung WY, So WY, Tong PC, et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 2004; 19:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/137\">",
"      Parving HH, Lehnert H, Br&ouml;chner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/138\">",
"      Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/139\">",
"      Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/140\">",
"      Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 1990; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/141\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/142\">",
"      Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/143\">",
"      K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(2 Suppl 2):S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/144\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/145\">",
"      Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/146\">",
"      Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/147\">",
"      Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/148\">",
"      Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/149\">",
"      Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/150\">",
"      Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991; 14 Suppl 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/151\">",
"      Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999; 34:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/152\">",
"      Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/153\">",
"      Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/154\">",
"      Bakris, GL. Salt intake and its impact on hypertension. Cardiovasc Rev Rep 2000; 21:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/155\">",
"      Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45:S145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/156\">",
"      Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/157\">",
"      Ruilope L, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press 2007; 16:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/48/40714/abstract/158\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3052 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40714=[""].join("\n");
var outline_f39_48_40714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANGIOTENSIN INHIBITION FOR PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ROLE OF OTHER FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PPAR-gamma agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRESERVATION OF RENAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Remission or regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Renal protection with ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Renal protection with ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16004841\">",
"      - Aliskiren plus angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1254778\">",
"      - Bardoxolone methyl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Protein restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECT ON PROTEIN EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACE inhibitor or ARB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACE inhibitor plus ARB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ARB plus aliskiren",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Aldosterone antagonism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other antihypertensive drugs and combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Salt intake and proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      WEIGHT REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HYPERLIPIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMBINED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Measurement of protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Therapeutic goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Protein restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3052\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3052|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/21/18781\" title=\"figure 1\">",
"      Nephropathy and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/43/30384\" title=\"figure 2\">",
"      Reversal of diabetic nephropathy after pancreas TPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/48/15117\" title=\"figure 3\">",
"      ACEI vs other drugs in DM rats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/50/14125\" title=\"figure 4\">",
"      ACEI delays moderately increased albuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/22/29037\" title=\"figure 5\">",
"      ACEI in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/52/27469\" title=\"figure 6\">",
"      Systolic BP in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/60/18382\" title=\"figure 7\">",
"      Irbesartan in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/13/15581\" title=\"figure 8\">",
"      Low protein preserves GFR in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/48/24333\" title=\"figure 9\">",
"      AHT drugs and proteinuria in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/28/17870\" title=\"figure 10\">",
"      Combination Rx and proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/36/6734\" title=\"figure 11\">",
"      ACEI vs Ca blocker in CRF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/53/41821\" title=\"figure 12\">",
"      Number BPmeds HTNcontrol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/53/17245\" title=\"figure 13\">",
"      Aggressive BP reduction in CRF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3052|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/8/11399\" title=\"picture 1\">",
"      Unilateral KW disease Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3052|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/1/5148\" title=\"table 1\">",
"      Treatment goals Steno type 2 study",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22484?source=related_link\">",
"      Mechanisms of glomerular hyperfiltration in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24644?source=related_link\">",
"      Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_48_40715="Viral versus bacterial sinusitis";
var content_f39_48_40715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristic features of viral versus bacterial rhinosinusitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Viral rhinosinusitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bacterial rhinosinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        Fever is typically absent, but when present",
"        <strong>",
"         occurs early (in first 24 hours)",
"        </strong>",
"        , is low-grade, and resolves within the first&nbsp;two days",
"       </td>",
"       <td>",
"        In severe presentation, temperature may be &ge;39&deg;C (102.2&deg;F) for &gt;3 days; in worsening presentation, fever may develop or recur on day 6 to 7 of illness after initial improvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal discharge",
"       </td>",
"       <td>",
"        Peaks on days 3 to 6 of illness and then steadily improves",
"       </td>",
"       <td>",
"        Fails to improve or worsens over time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough",
"       </td>",
"       <td>",
"        Peaks on days 3 to 6 of illness and then steadily improves",
"       </td>",
"       <td>",
"        Fails to improve or worsens over time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ill-appearance",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        May occur (in severe presentation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe headache",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        May be a sign of severe illness or complication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical course",
"       </td>",
"       <td>",
"        Symptoms peak in severity on days 3 to 6 and then improve",
"       </td>",
"       <td>",
"        Symptoms are present for &ge;10 days",
"        <strong>",
"         without improvement",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40715=[""].join("\n");
var outline_f39_48_40715=null;
var title_f39_48_40716="Foods that contain gluten PI";
var content_f39_48_40716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Foods that contain gluten",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Foods that definitely contain gluten:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheat (einkorn, durum, faro, graham, kamut, semolina, spelt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barley",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt, malt flavoring, malt extract derived from barley",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt vinegar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triticale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Foods that might contain gluten:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beers, ales, and lagers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breading, bread crumbs, and coating mixes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brewer's yeast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broth, bouillon, or soup stock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown rice syrup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cake frosting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candy and licorice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Communion wafers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condiments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Croutons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dates (if rolled in oat flour)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drink mixes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy bars",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flavored teas and coffees",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flour or cereal products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imitation products, like bacon or seafood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Matzo and matzo meal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medicines (both over-the-counter and prescription)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oats (unless they are labeled \"gluten free\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Processed lunch meats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rice pilaf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salad dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sauces, gravies, marinades, and thickeners",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seasonings, spices, and smoke flavoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seasoned chips, nuts, and seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-basting poultry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soy sauce",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stuffing (for poultry)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamins and herbal supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Play products for children:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Play-dough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paper mache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some of these play products are made from flour or contain gluten. Children with celiac disease can play with these products, but they should wash their hands after playing.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For the foods that might contain gluten, it depends on their ingredients and where they were made. To know for sure, you will need to check the ingredient label.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40716=[""].join("\n");
var outline_f39_48_40716=null;
var title_f39_48_40717="Contents: Dermatologic diagnosis";
var content_f39_48_40717=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Dermatologic diagnosis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Dermatologic diagnosis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/28/37318\">",
"           Approach to the patient with a scalp eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/54/35688\">",
"           Approach to the patient with annular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/54/14186\">",
"           Approach to the patient with cutaneous blisters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/34/552\">",
"           Approach to the patient with facial erythema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/8/29831\">",
"           Approach to the patient with macular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/48/28423\">",
"           Approach to the patient with pustular skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/43/39608\">",
"           Approach to the patient with retiform (angulated) purpura",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/51/31543\">",
"           Dermatologic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/11/13497\">",
"           Dermoscopic evaluation of skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/4/13385\">",
"           Erythroderma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/15/4345\">",
"           Evaluation of adults with cutaneous lesions of vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/57/38807\">",
"           Overview of dermoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/15/36090\">",
"           Overview of nail disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/31/28150\">",
"           Patch testing",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3C22FC7B3B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f39_48_40717=[""].join("\n");
var outline_f39_48_40717=null;
var title_f39_48_40718="Contents: Coronary revascularization";
var content_f39_48_40718=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Coronary revascularization",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Coronary revascularization",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Angina pectoris",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31576\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/38/27240\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/61/24536\">",
"           Late recurrent angina pectoris after coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/51/9018\">",
"           Medical therapy versus revascularization in the management of stable angina pectoris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/32/28167\">",
"           Transmyocardial laser revascularization for management of refractory angina",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary artery bypass grafting",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31576\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39368\">",
"           Early cardiac complications of coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/25/35226\">",
"           Early noncardiac complications of coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/61/24536\">",
"           Late recurrent angina pectoris after coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/2/37930\">",
"           Long-term outcome after coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/26/40360\">",
"           Medical therapy to prevent complications after coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/16/44296\">",
"           Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/10/37031\">",
"           Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/38/22120\">",
"           Operative mortality after coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/7/2168\">",
"           Prevention of neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/58/26538\">",
"           Prevention, presentation, and management of saphenous vein graft stenosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/27/34234\">",
"           Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/42/20138\">",
"           Role of stress testing after coronary revascularization",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Percutaneous coronary intervention and stenting",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/24/10634\">",
"           Antiplatelet therapy after coronary artery stenting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/37/41562\">",
"           Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/8/27786\">",
"           Antithrombotic therapy for percutaneous coronary intervention: General use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/38/27240\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/62/16360\">",
"           Comparison of drug-eluting intracoronary stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/15/30970\">",
"           Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/25/9623\">",
"           Coronary artery stent thrombosis: Clinical presentation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/59/9146\">",
"           Coronary artery stent thrombosis: Incidence and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/61/34773\">",
"           Coronary artery stent types in development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/30/27108\">",
"           Coronary complications of atheroablative devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1081\">",
"           Drug-eluting compared to bare metal intracoronary stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/43/43702\">",
"           Drug-eluting intracoronary stents: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/19/24889\">",
"           General principles of the use of intracoronary stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/46/24298\">",
"           Intracoronary stent restenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/20/4426\">",
"           Management of left main coronary artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/51/9018\">",
"           Medical therapy versus revascularization in the management of stable angina pectoris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/9/20632\">",
"           Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/9/40089\">",
"           Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/48/38666\">",
"           Periprocedural complications of percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/51/39737\">",
"           Periprocedural myocardial infarction following percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/25/29081\">",
"           Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/42/20138\">",
"           Role of stress testing after coronary revascularization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/11/41142\">",
"           Specialized revascularization devices in the management of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/61/25560\">",
"           Use of intracoronary radiation to prevent restenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/22/17770\">",
"           Use of intracoronary stents for specific coronary lesions",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-93FCF8C086-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f39_48_40718=[""].join("\n");
var outline_f39_48_40718=null;
var title_f39_48_40719="Fetal schizencephaly";
var content_f39_48_40719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal schizencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fetus at 31 weeks with schizencephaly. Note the cleft in the brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_48_40719=[""].join("\n");
var outline_f39_48_40719=null;
